<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Amyotrophic Lateral Sclerosis - Disorder Mechanisms</title>
    <style>
        :root {
            --primary: #0f766e;
            --primary-light: #14b8a6;
            --primary-dark: #0d5c56;
            --secondary: #6366f1;
            --bg: #f0fdfa;
            --card-bg: #ffffff;
            --text: #134e4a;
            --text-muted: #5f7a78;
            --border: #ccfbf1;
            --accent-orange: #f59e0b;
            --accent-rose: #f43f5e;
            --accent-violet: #8b5cf6;
            --accent-sky: #0ea5e9;
            --banner-bg: #fef3c7;
            --banner-border: #f59e0b;
            --banner-text: #92400e;
        }

        * { box-sizing: border-box; margin: 0; padding: 0; }

        body {
            font-family: 'Segoe UI', system-ui, -apple-system, sans-serif;
            background: var(--bg);
            color: var(--text);
            line-height: 1.7;
        }

        .notice-banner {
            background: var(--banner-bg);
            color: var(--banner-text);
            border-bottom: 1px solid var(--banner-border);
            padding: 12px 16px;
            text-align: center;
            font-size: 0.95rem;
            cursor: pointer;
        }

        .container {
            max-width: 1100px;
            margin: 0 auto;
            padding: 24px;
        }

        /* Header */
        .page-header {
            background: linear-gradient(135deg, var(--primary) 0%, var(--primary-dark) 100%);
            color: white;
            padding: 40px 32px;
            border-radius: 16px;
            margin-bottom: 24px;
            position: relative;
            overflow: hidden;
        }

        .page-header::before {
            content: '';
            position: absolute;
            top: -50%;
            right: -20%;
            width: 400px;
            height: 400px;
            background: rgba(255,255,255,0.05);
            border-radius: 50%;
        }

        .page-header h1 {
            font-size: 2.2rem;
            font-weight: 700;
            margin-bottom: 12px;
            position: relative;
        }

        .header-meta {
            display: flex;
            flex-wrap: wrap;
            gap: 12px;
            align-items: center;
            position: relative;
        }

        .header-dates {
            display: flex;
            flex-wrap: wrap;
            gap: 10px;
            margin-top: 16px;
            padding-top: 12px;
            border-top: 1px solid rgba(255,255,255,0.22);
            position: relative;
        }

        .date-chip {
            display: inline-flex;
            align-items: center;
            gap: 6px;
            background: rgba(255,255,255,0.14);
            border: 1px solid rgba(255,255,255,0.25);
            border-radius: 999px;
            padding: 5px 10px;
            font-size: 0.82rem;
        }

        .date-chip-label {
            font-weight: 600;
            opacity: 0.95;
        }

        .date-chip time {
            font-variant-numeric: tabular-nums;
        }

        .badge {
            display: inline-flex;
            align-items: center;
            padding: 6px 14px;
            border-radius: 20px;
            font-size: 0.85rem;
            font-weight: 500;
        }

        .badge-category {
            background: rgba(255,255,255,0.2);
            color: white;
        }

        .badge-mondo {
            background: var(--accent-sky);
            color: white;
        }

        .badge-mondo a {
            color: inherit;
            text-decoration: none;
        }

        .badge-mondo a:hover {
            text-decoration: underline;
        }

        /* Navigation */
        .breadcrumb {
            margin-bottom: 16px;
            font-size: 0.9rem;
        }

        .breadcrumb a {
            color: var(--primary);
            text-decoration: none;
        }

        .breadcrumb a:hover {
            text-decoration: underline;
        }

        .breadcrumb span {
            color: var(--text-muted);
        }

        /* Cards */
        .card {
            background: var(--card-bg);
            border-radius: 12px;
            border: 1px solid var(--border);
            padding: 24px;
            margin-bottom: 20px;
            box-shadow: 0 1px 3px rgba(0,0,0,0.04);
        }

        .card-header {
            display: flex;
            align-items: center;
            gap: 12px;
            margin-bottom: 16px;
            padding-bottom: 12px;
            border-bottom: 2px solid var(--border);
        }

        .card-icon {
            width: 36px;
            height: 36px;
            border-radius: 8px;
            display: flex;
            align-items: center;
            justify-content: center;
            font-size: 1.2rem;
        }

        .card-title {
            font-size: 1.1rem;
            font-weight: 600;
            color: var(--text);
        }

        .card-count {
            margin-left: auto;
            background: var(--bg);
            padding: 4px 12px;
            border-radius: 12px;
            font-size: 0.8rem;
            color: var(--text-muted);
        }

        /* Sections */
        .section-grid {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(320px, 1fr));
            gap: 20px;
        }

        /* Tags */
        .tag-list {
            display: flex;
            flex-wrap: wrap;
            gap: 8px;
        }

        .tag {
            padding: 6px 12px;
            border-radius: 6px;
            font-size: 0.85rem;
            font-weight: 500;
        }

        .tag-cell {
            background: #fce7f3;
            color: #9d174d;
        }

        .tag-gene {
            background: #dbeafe;
            color: #1e40af;
        }

        .tag-treatment {
            background: #ede9fe;
            color: #5b21b6;
        }

        .tag-env {
            background: #ccfbf1;
            color: #0f766e;
        }

        .tag-location {
            background: #e0e7ff;
            color: #3730a3;
        }

        .tag-component {
            background: #f0fdf4;
            color: #166534;
        }

        .tag-complex {
            background: #faf5ff;
            color: #7e22ce;
        }

        .tag-bio {
            background: #fef3c7;
            color: #92400e;
        }

        .tag-modifier {
            background: #fee2e2;
            color: #991b1b;
            text-transform: uppercase;
            letter-spacing: 0.02em;
        }

        .tag-parent {
            background: #e0e7ff;
            color: #3730a3;
        }

        .tag-classification {
            background: #fef3c7;
            color: #92400e;
        }

        .tag-mechanistic {
            background: #dbeafe;
            color: #1e40af;
        }

        .linkout {
            color: inherit;
            margin-left: 6px;
            font-size: 0.75rem;
            text-decoration: none;
            border-bottom: 1px dotted rgba(0, 0, 0, 0.2);
        }

        .classification-category {
            font-size: 0.75rem;
            font-weight: 600;
            text-transform: uppercase;
            letter-spacing: 0.05em;
            color: var(--text-muted);
            margin-bottom: 8px;
        }

        .mapping-section {
            margin-bottom: 16px;
        }

        .mapping-item {
            padding: 10px 12px;
            border: 1px solid #e2e8f0;
            border-radius: 8px;
            background: #ffffff;
            margin-bottom: 10px;
        }

        .mapping-title {
            font-size: 0.9rem;
            font-weight: 600;
            display: flex;
            flex-wrap: wrap;
            gap: 8px;
            align-items: baseline;
            margin-bottom: 6px;
        }

        .mapping-label {
            color: var(--text-muted);
            font-weight: 500;
        }

        .mapping-notes {
            font-size: 0.85rem;
            color: var(--text-muted);
            margin-top: 6px;
        }

        .mapping-tree {
            margin-top: 6px;
            font-size: 0.75rem;
            color: var(--text-muted);
            list-style: none;
            padding-left: 0;
        }

        .mapping-tree li {
            margin: 2px 0;
        }

        /* Evidence styling */
        .evidence-toggle {
            cursor: pointer;
            font-size: 0.8rem;
            color: var(--text-muted);
            margin-top: 10px;
            user-select: none;
        }

        .evidence-toggle:hover {
            color: var(--primary);
        }

        .evidence-list {
            margin-top: 10px;
            padding-left: 0;
        }

        .evidence-item {
            padding: 12px 14px;
            background: #f8fafc;
            border-radius: 8px;
            margin-bottom: 8px;
            border: 1px solid #e2e8f0;
            font-size: 0.9rem;
        }

        .evidence-header {
            display: flex;
            align-items: center;
            flex-wrap: wrap;
            gap: 8px;
        }

        .evidence-ref {
            font-weight: 600;
            color: var(--secondary);
        }

        .evidence-ref a {
            color: inherit;
            text-decoration: none;
        }

        .evidence-ref a:hover {
            text-decoration: underline;
        }

        .evidence-support {
            font-size: 0.7rem;
            padding: 2px 8px;
            border-radius: 4px;
            font-weight: 600;
            text-transform: uppercase;
            transition: transform 120ms ease, box-shadow 120ms ease;
        }

        .support-SUPPORT { background: #dcfce7; color: #166534; }
        .support-PARTIAL { background: #fef3c7; color: #92400e; }
        .support-REFUTE { background: #fee2e2; color: #991b1b; }
        .support-NO_EVIDENCE { background: #f1f5f9; color: #64748b; }
        .support-WRONG_STATEMENT { background: #fecaca; color: #7f1d1d; }

        .evidence-source {
            font-size: 0.7rem;
            padding: 2px 8px;
            border-radius: 4px;
            font-weight: 600;
            text-transform: uppercase;
            background: #e2e8f0;
            color: #334155;
            transition: transform 120ms ease, box-shadow 120ms ease;
        }

        .evidence-support:hover,
        .evidence-source:hover {
            transform: translateY(-1px);
            box-shadow: 0 4px 10px rgba(0,0,0,0.08);
        }

        .source-HUMAN_CLINICAL { background: #e0f2fe; color: #075985; }
        .source-MODEL_ORGANISM { background: #fef9c3; color: #854d0e; }
        .source-IN_VITRO { background: #ede9fe; color: #5b21b6; }
        .source-COMPUTATIONAL { background: #cffafe; color: #0e7490; }
        .source-OTHER { background: #e5e7eb; color: #374151; }

        .evidence-snippet {
            font-size: 0.85rem;
            color: var(--text-muted);
            margin-top: 8px;
            padding-left: 12px;
            border-left: 2px solid #cbd5e1;
            font-style: italic;
            line-height: 1.5;
        }

        .evidence-explanation {
            font-size: 0.85rem;
            color: var(--text);
            margin-top: 6px;
            line-height: 1.5;
        }

        .evidence-more {
            font-size: 0.8rem;
            color: var(--text-muted);
            margin-top: 6px;
            font-style: italic;
        }

        .findings-section {
            margin-top: 12px;
        }

        .findings-title {
            font-size: 0.75rem;
            font-weight: 600;
            text-transform: uppercase;
            letter-spacing: 0.04em;
            color: var(--text-muted);
            margin-bottom: 6px;
        }

        .finding-item {
            padding: 10px 12px;
            background: #f8fafc;
            border-radius: 8px;
            margin-bottom: 8px;
            border: 1px solid #e2e8f0;
            font-size: 0.9rem;
        }

        .finding-statement {
            font-weight: 600;
            color: var(--text);
            margin-bottom: 6px;
            line-height: 1.5;
        }

        .finding-supporting {
            font-size: 0.85rem;
            color: var(--text-muted);
            margin-top: 6px;
            padding-left: 12px;
            border-left: 2px solid #cbd5e1;
            font-style: italic;
            line-height: 1.5;
        }

        /* Item containers with evidence */
        .item-box {
            padding: 16px;
            border-radius: 10px;
            margin-bottom: 12px;
        }

        .item-name {
            font-weight: 600;
            margin-bottom: 6px;
        }

        .item-desc {
            font-size: 0.9rem;
            line-height: 1.6;
            margin-bottom: 8px;
        }

        .item-meta {
            display: flex;
            flex-wrap: wrap;
            gap: 6px;
            margin-top: 8px;
        }

        /* Definitions */
        .definition-box {
            background: #ecfeff;
            border-left: 4px solid #0ea5e9;
        }
        .definition-box .item-name { color: #0c4a6e; }
        .definition-box .item-desc { color: #075985; }

        /* Inheritance */
        .inheritance-box {
            background: #fef9c3;
            border-left: 4px solid #ca8a04;
        }
        .inheritance-box .item-name { color: #92400e; }
        .inheritance-box .item-desc { color: #92400e; }

        .criteria-block {
            margin-top: 12px;
            padding: 12px;
            border-radius: 8px;
            border: 1px solid #bae6fd;
            background: rgba(255, 255, 255, 0.7);
        }

        .criteria-title {
            font-weight: 600;
            color: #0c4a6e;
            margin-bottom: 6px;
        }

        .criteria-meta {
            font-size: 0.8rem;
            color: var(--text-muted);
            margin-bottom: 8px;
        }

        .criteria-header {
            font-size: 0.75rem;
            text-transform: uppercase;
            letter-spacing: 0.04em;
            color: #0284c7;
            margin-top: 8px;
        }

        .criteria-list {
            margin-left: 18px;
            font-size: 0.9rem;
            line-height: 1.5;
            color: #0f172a;
        }

        .criteria-list li {
            margin-bottom: 6px;
        }

        .criteria-detail {
            display: block;
            font-size: 0.85rem;
            color: var(--text-muted);
        }

        /* Pathophysiology */
        .pathophys-box {
            background: linear-gradient(135deg, #fef3c7 0%, #fef9c3 100%);
            border-left: 4px solid var(--accent-orange);
        }
        .pathophys-box .item-name { color: #92400e; }
        .pathophys-box .item-desc { color: #78350f; }

        /* Histopathology */
        .histopathology-box {
            background: #fff7ed;
            border-left: 4px solid #fb923c;
        }
        .histopathology-box .item-name { color: #9a3412; }
        .histopathology-box .item-desc { color: #c2410c; }

        .histopathology-freq {
            font-size: 0.75rem;
            padding: 2px 8px;
            border-radius: 10px;
            background: #ffedd5;
            color: #c2410c;
        }

        /* Phenotypes */
        .phenotype-box {
            background: #f0fdf4;
            border-left: 4px solid #22c55e;
        }
        .phenotype-box .item-name { color: #166534; }
        .phenotype-box .item-desc { color: #15803d; }

        .phenotype-freq {
            font-size: 0.75rem;
            padding: 2px 8px;
            border-radius: 10px;
            background: #dcfce7;
            color: #15803d;
        }

        .phenotype-category {
            font-size: 0.75rem;
            color: #4ade80;
        }

        .phenotype-id a {
            font-size: 0.8rem;
            color: var(--secondary);
            text-decoration: none;
        }

        .phenotype-id a:hover {
            text-decoration: underline;
        }

        /* Phenotype TOC strip */
        .pheno-toc {
            display: flex;
            flex-wrap: wrap;
            gap: 6px;
            padding: 10px 0 6px 0;
            border-bottom: 1px solid #e2e8f0;
            margin-bottom: 4px;
        }

        .pheno-toc-pill {
            display: inline-block;
            font-size: 0.78rem;
            padding: 3px 10px;
            border-radius: 12px;
            background: #dcfce7;
            color: #166534;
            text-decoration: none;
            cursor: pointer;
            white-space: nowrap;
            transition: background 0.15s;
        }

        .pheno-toc-pill:hover {
            background: #bbf7d0;
        }

        .pheno-toc-pill .pill-count {
            font-weight: 600;
            margin-left: 2px;
        }

        .pheno-toggle-all {
            font-size: 0.78rem;
            color: #16a34a;
            cursor: pointer;
            background: none;
            border: 1px solid #bbf7d0;
            border-radius: 6px;
            padding: 3px 10px;
            margin-left: auto;
            white-space: nowrap;
            transition: background 0.15s;
        }

        .pheno-toggle-all:hover {
            background: #f0fdf4;
        }

        /* Collapsible category groups */
        .phenotype-category-group {
            margin-bottom: 2px;
        }

        .phenotype-category-group summary {
            font-size: 0.85rem;
            font-weight: 600;
            text-transform: uppercase;
            letter-spacing: 0.04em;
            color: #16a34a;
            margin: 0;
            padding: 10px 0 6px 0;
            border-bottom: 1px solid #bbf7d0;
            cursor: pointer;
            list-style: none;
            display: flex;
            align-items: center;
            gap: 6px;
        }

        .phenotype-category-group summary::-webkit-details-marker {
            display: none;
        }

        .phenotype-category-group summary .chevron {
            display: inline-block;
            width: 16px;
            height: 16px;
            transition: transform 0.15s;
            flex-shrink: 0;
        }

        .phenotype-category-group[open] summary .chevron {
            transform: rotate(90deg);
        }

        .phenotype-category-group summary .cat-count {
            font-size: 0.75rem;
            font-weight: 400;
            color: #15803d;
            background: #dcfce7;
            padding: 1px 7px;
            border-radius: 8px;
        }

        /* Phenotype Contexts */
        .phenotype-contexts {
            margin-top: 10px;
        }

        .phenotype-contexts-toggle {
            font-size: 0.8rem;
            color: var(--text-muted);
            cursor: pointer;
            user-select: none;
        }

        .phenotype-contexts-toggle:hover {
            color: var(--primary);
        }

        .context-card {
            padding: 10px 14px;
            margin-top: 8px;
            border-radius: 8px;
            background: #ecfdf5;
            border: 1px solid #a7f3d0;
            font-size: 0.88rem;
        }

        .context-header {
            display: flex;
            flex-wrap: wrap;
            align-items: center;
            gap: 6px;
            margin-bottom: 6px;
        }

        .context-label {
            font-size: 0.72rem;
            font-weight: 600;
            text-transform: uppercase;
            letter-spacing: 0.04em;
            padding: 2px 8px;
            border-radius: 4px;
        }

        .context-label-genetic {
            background: #dbeafe;
            color: #1e40af;
        }

        .context-label-sex {
            background: #fce7f3;
            color: #9d174d;
        }

        .context-label-population {
            background: #fef3c7;
            color: #92400e;
        }

        .context-label-age {
            background: #e0e7ff;
            color: #3730a3;
        }

        .context-label-subtype {
            background: #ede9fe;
            color: #5b21b6;
        }

        .context-label-frequency {
            background: #dcfce7;
            color: #166534;
        }

        .context-gene-list {
            display: flex;
            flex-wrap: wrap;
            gap: 4px;
            margin: 4px 0;
        }

        .context-gene-tag {
            font-size: 0.78rem;
            font-weight: 600;
            padding: 1px 8px;
            border-radius: 4px;
            background: #bfdbfe;
            color: #1e3a8a;
        }

        .context-detail {
            font-size: 0.84rem;
            color: #065f46;
            line-height: 1.5;
        }

        .context-detail strong {
            color: #047857;
        }

        .context-freq {
            font-size: 0.75rem;
            padding: 2px 8px;
            border-radius: 10px;
            background: #bbf7d0;
            color: #14532d;
            font-weight: 600;
        }

        .context-onset {
            font-size: 0.75rem;
            padding: 2px 8px;
            border-radius: 10px;
            background: #e0e7ff;
            color: #3730a3;
        }

        .context-severity {
            font-size: 0.75rem;
            padding: 2px 8px;
            border-radius: 10px;
            background: #fef3c7;
            color: #92400e;
        }

        .context-notes {
            font-size: 0.84rem;
            color: #065f46;
            margin-top: 4px;
            line-height: 1.5;
        }

        /* Genetic */
        .genetic-box {
            background: #eff6ff;
            border-left: 4px solid #3b82f6;
        }
        .genetic-box .item-name { color: #1e40af; }
        .genetic-box .item-desc { color: #2563eb; }

        /* Treatment */
        .treatment-box {
            background: #faf5ff;
            border-left: 4px solid #8b5cf6;
        }
        .treatment-box .item-name { color: #5b21b6; }
        .treatment-box .item-desc { color: #7c3aed; }

        /* Environmental */
        .environmental-box {
            background: #f0fdfa;
            border-left: 4px solid #14b8a6;
        }
        .environmental-box .item-name { color: #0f766e; }
        .environmental-box .item-desc { color: #0d9488; }

        /* Biochemical */
        .biochemical-box {
            background: #fffbeb;
            border-left: 4px solid #f59e0b;
        }
        .biochemical-box .item-name { color: #92400e; }
        .biochemical-box .item-desc { color: #b45309; }

        /* Differential Diagnoses */
        .differential-box {
            background: #fef2f2;
            border-left: 4px solid #dc2626;
        }
        .differential-box .item-name { color: #7f1d1d; }
        .differential-box .item-desc { color: #b91c1c; }

        .differential-similarities {
            background: #fee2e2;
            border-left: 2px solid #dc2626;
            padding: 10px 12px;
            border-radius: 6px;
            margin: 8px 0;
            font-size: 0.9rem;
        }

        .differential-distinctions {
            background: #dcfce7;
            border-left: 2px solid #16a34a;
            padding: 10px 12px;
            border-radius: 6px;
            margin: 8px 0;
            font-size: 0.9rem;
        }

        .differential-similarities strong,
        .differential-distinctions strong {
            display: block;
            margin-bottom: 6px;
            font-size: 0.85rem;
            text-transform: uppercase;
            letter-spacing: 0.05em;
        }

        .differential-similarities ul,
        .differential-distinctions ul {
            margin-left: 16px;
            line-height: 1.6;
        }

        .differential-similarities li,
        .differential-distinctions li {
            margin: 4px 0;
            font-size: 0.9rem;
        }

        /* Datasets */
        .dataset-box {
            background: #f0f9ff;
            border-left: 4px solid #0284c7;
        }
        .dataset-box .item-name { color: #0c4a6e; }
        .dataset-box .item-desc { color: #0369a1; }

        .tag-dataset {
            background: #e0f2fe;
            color: #0369a1;
        }

        .tag-organism {
            background: #fae8ff;
            color: #a21caf;
        }

        .tag-datatype {
            background: #dbeafe;
            color: #1d4ed8;
        }

        /* Clinical Trials */
        .clinical-trial-box {
            background: #f5f3ff;
            border-left: 4px solid #a855f7;
        }
        .clinical-trial-box .item-name { color: #6b21a8; }
        .clinical-trial-box .item-desc { color: #7e22ce; }

        .tag-phase {
            background: #ede9fe;
            color: #6b21a8;
        }

        .tag-status {
            background: #fce7f3;
            color: #9d174d;
        }

        .trial-nct a {
            font-family: 'Fira Code', 'Consolas', monospace;
            font-size: 0.85rem;
            color: var(--secondary);
            text-decoration: none;
        }

        .trial-nct a:hover {
            text-decoration: underline;
        }

        .dataset-accession a {
            font-family: 'Fira Code', 'Consolas', monospace;
            font-size: 0.85rem;
            color: var(--secondary);
            text-decoration: none;
        }

        .dataset-accession a:hover {
            text-decoration: underline;
        }

        /* Subtypes */
        .subtype-box {
            background: #eef2ff;
            border-left: 4px solid var(--secondary);
        }
        .subtype-box .item-name { color: #3730a3; }
        .subtype-box .item-desc { color: #4f46e5; }
        .classification-header {
            font-size: 1rem;
            font-weight: 600;
            color: #4338ca;
            margin: 1.2rem 0 0.5rem 0;
            padding-bottom: 0.3rem;
            border-bottom: 2px solid #c7d2fe;
            text-transform: capitalize;
        }
        .subtype-meta {
            display: flex;
            flex-wrap: wrap;
            gap: 0.4rem;
            margin: 0.3rem 0;
        }
        .subtype-freq-badge {
            background: #dbeafe;
            color: #1e40af;
            padding: 0.15rem 0.5rem;
            border-radius: 9999px;
            font-size: 0.8rem;
            font-weight: 500;
        }
        .subtype-gene-tag {
            background: #fef3c7;
            color: #92400e;
            padding: 0.15rem 0.5rem;
            border-radius: 9999px;
            font-size: 0.8rem;
            font-weight: 500;
        }
        .subtype-inheritance-tag {
            background: #ede9fe;
            color: #5b21b6;
            padding: 0.15rem 0.5rem;
            border-radius: 9999px;
            font-size: 0.8rem;
            font-weight: 500;
        }
        .subtype-term-link {
            font-size: 0.8rem;
            color: #6366f1;
            text-decoration: none;
        }
        .subtype-term-link:hover { text-decoration: underline; }
        .subtype-children {
            margin: 0.4rem 0 0.2rem 1rem;
            padding: 0;
            list-style: none;
        }
        .subtype-children li {
            font-size: 0.85rem;
            color: #4338ca;
            padding: 0.1rem 0;
        }
        .subtype-children li::before {
            content: "↳ ";
            color: #a5b4fc;
        }

        /* Stats bar */
        .stats-bar {
            display: flex;
            gap: 24px;
            padding: 20px 24px;
            background: var(--card-bg);
            border-radius: 12px;
            border: 1px solid var(--border);
            margin-bottom: 24px;
            flex-wrap: wrap;
        }

        .stat-item {
            text-align: center;
        }

        .stat-link {
            text-decoration: none;
            color: inherit;
        }

        .stat-value {
            font-size: 1.5rem;
            font-weight: 700;
            color: var(--primary);
        }

        .stat-label {
            font-size: 0.8rem;
            color: var(--text-muted);
            text-transform: uppercase;
            letter-spacing: 0.05em;
        }

        /* YAML preview */
        .yaml-preview {
            background: #1e293b;
            color: #e2e8f0;
            padding: 20px;
            border-radius: 8px;
            overflow-x: auto;
            font-family: 'Fira Code', 'Consolas', monospace;
            font-size: 0.85rem;
            line-height: 1.5;
            max-height: 400px;
            overflow-y: auto;
        }

        .yaml-content {
            display: none;
        }

        .yaml-content.show {
            display: block;
        }

        /* Footer */
        .page-footer {
            margin-top: 40px;
            padding-top: 20px;
            border-top: 1px solid var(--border);
            text-align: center;
            color: var(--text-muted);
            font-size: 0.85rem;
        }

        .page-footer a {
            color: var(--primary);
            text-decoration: none;
        }

        .page-footer a:hover {
            text-decoration: underline;
        }

        /* Responsive */
        @media (max-width: 768px) {
            .page-header h1 { font-size: 1.6rem; }
            .stats-bar { gap: 16px; }
            .section-grid { grid-template-columns: 1fr; }
        }
        /* Mermaid graph */
        .mermaid-container {
            text-align: center;
            margin: 20px 0;
            padding: 20px;
            background: white;
            border-radius: 8px;
            border: 1px solid var(--border);
            overflow-x: auto;
        }

        .mermaid svg {
            max-width: 100%;
            height: auto;
        }

        .graph-warning {
            background: #fef3c7;
            border: 1px solid #f59e0b;
            border-radius: 8px;
            padding: 12px 16px;
            margin-bottom: 16px;
            font-size: 0.85rem;
            color: #92400e;
        }

        .graph-warning strong {
            display: block;
            margin-bottom: 4px;
        }

        .graph-warning ul {
            margin: 8px 0 0 20px;
            padding: 0;
        }

        .graph-warning li {
            margin: 4px 0;
        }
    </style>
    <script src="https://cdn.jsdelivr.net/npm/mermaid@10/dist/mermaid.min.js"></script>
    <script>
        mermaid.initialize({
            startOnLoad: true,
            theme: 'default',
            flowchart: {
                htmlLabels: true,
                curve: 'basis'
            }
        });
    </script>
</head>
<body>
    <div class="notice-banner" role="button" tabindex="0">This resource is in its pre-alpha development stage. Content is actively being curated and may be incomplete or subject to change.</div>
    

    

    
    

    
    

    

    

    

    

    

    <div class="container">
        <nav class="breadcrumb">
            <a href="../../app/index.html">Browse All</a>
            <span> / </span>
            <span>Amyotrophic Lateral Sclerosis</span>
        </nav>

        <header class="page-header">
            <h1>Amyotrophic Lateral Sclerosis</h1>
            <div class="header-meta">
                
                <span class="badge badge-category">Complex</span>
                
                
                <span class="badge badge-mondo">
                    <a href="http://purl.obolibrary.org/obo/MONDO_0004976" target="_blank">
                        MONDO:0004976
                    </a>
                </span>
                
                
                <span class="badge badge-category" style="background: rgba(255,255,255,0.1);">Motor Neuron Disease</span>
                
                <span class="badge badge-category" style="background: rgba(255,255,255,0.1);">Neurodegenerative Disease</span>
                
            </div>
            
            <p style="margin-top: 16px; font-size: 1rem; line-height: 1.6; opacity: 0.95; position: relative;">
                Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig&#39;s disease, is a progressive neurodegenerative disorder characterized by the selective death of upper and lower motor neurons in the brain, brainstem, and spinal cord. This leads to progressive muscle weakness, atrophy, spasticity, and ultimately respiratory failure. ALS typically presents in adulthood with a median survival of 3-5 years from symptom onset. Approximately 5-10% of cases are familial, with the remainder being sporadic. A hallmark feature is TDP-43 proteinopathy, present in approximately 97% of cases.

            </p>
            
            
        </header>

        <!-- Stats bar -->
        
        
        
        
        
        
        
        
        
        
        
        
        
        <div class="stats-bar">
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Mappings</div>
            </div>
            
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Definitions</div>
            </div>
            
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Inheritance</div>
            </div>
            
            
            <a class="stat-link" href="#pathophysiology">
            <div class="stat-item">
                <div class="stat-value">10</div>
                <div class="stat-label">Pathophysiology</div>
            </div>
            </a>
            
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Histopathology</div>
            </div>
            
            
            <a class="stat-link" href="#phenotypes">
            <div class="stat-item">
                <div class="stat-value">8</div>
                <div class="stat-label">Phenotypes</div>
            </div>
            </a>
            
            
            <a class="stat-link" href="#genetic">
            <div class="stat-item">
                <div class="stat-value">5</div>
                <div class="stat-label">Genes</div>
            </div>
            </a>
            
            
            <a class="stat-link" href="#treatments">
            <div class="stat-item">
                <div class="stat-value">8</div>
                <div class="stat-label">Treatments</div>
            </div>
            </a>
            
            
            <a class="stat-link" href="#subtypes">
            <div class="stat-item">
                <div class="stat-value">4</div>
                <div class="stat-label">Subtypes</div>
            </div>
            </a>
            
            
            <a class="stat-link" href="#differentials">
            <div class="stat-item">
                <div class="stat-value">3</div>
                <div class="stat-label">Differentials</div>
            </div>
            </a>
            
            
            <a class="stat-link" href="#datasets">
            <div class="stat-item">
                <div class="stat-value">2</div>
                <div class="stat-label">Datasets</div>
            </div>
            </a>
            
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Trials</div>
            </div>
            
        </div>

        <!-- Classifications -->
        

        <!-- Mappings -->
        

        <!-- Definitions -->
        

        <!-- Inheritance -->
        

        <!-- Subtypes -->
        
        <div class="card" id="subtypes">
            <div class="card-header">
                <div class="card-icon" style="background: #eef2ff; color: #4f46e5;">◆</div>
                <h2 class="card-title">Subtypes</h2>
                <span class="card-count">4</span>
            </div>
            
            
            
                
                
                    
                
                
            
                
                
                
            
                
                
                
            
                
                
                
            
            
                
                
                <div class="item-box subtype-box">
                    <div class="item-name">
                        Familial ALS
                        
                    </div>
                    <div class="subtype-meta">
                        
                        
                        
                    </div>
                    
                    <div class="item-desc">Hereditary form of ALS accounting for 5-10% of cases, with mutations in genes such as SOD1, C9orf72, TARDBP, and FUS.</div>
                    
                    
                    
    
    
                </div>
                
                <div class="item-box subtype-box">
                    <div class="item-name">
                        Sporadic ALS
                        
                    </div>
                    <div class="subtype-meta">
                        
                        
                        
                    </div>
                    
                    <div class="item-desc">Non-hereditary form of ALS accounting for 90-95% of cases with unclear etiology.</div>
                    
                    
                    
    
    
                </div>
                
                <div class="item-box subtype-box">
                    <div class="item-name">
                        Bulbar-onset ALS
                        
                    </div>
                    <div class="subtype-meta">
                        
                        
                        
                    </div>
                    
                    <div class="item-desc">ALS beginning with speech and swallowing difficulties due to bulbar motor neuron involvement.</div>
                    
                    
                    
    
    
                </div>
                
                <div class="item-box subtype-box">
                    <div class="item-name">
                        Limb-onset ALS
                        
                    </div>
                    <div class="subtype-meta">
                        
                        
                        
                    </div>
                    
                    <div class="item-desc">ALS beginning with limb weakness, the most common presentation.</div>
                    
                    
                    
    
    
                </div>
                
            
        </div>
        

        <!-- Comorbidities -->
        

        <!-- Pathophysiology -->
        
        <div class="card" id="pathophysiology">
            <div class="card-header">
                <div class="card-icon" style="background: #fef3c7; color: #d97706;">⚙</div>
                <h2 class="card-title">Pathophysiology</h2>
                <span class="card-count">10</span>
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Motor Neuron Degeneration</div>
                
                <div class="item-desc">Progressive death of upper motor neurons in the motor cortex and lower motor neurons in the brainstem and spinal cord leads to denervation of skeletal muscles. The loss of upper motor neurons causes spasticity and hyperreflexia, while lower motor neuron loss results in muscle weakness, atrophy, and fasciculations.
</div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-cell">
                        motor neuron
                        
                        <a href="http://purl.obolibrary.org/obo/CL_0000100" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-location">
                        primary motor cortex
                        
                        <a href="http://purl.obolibrary.org/obo/UBERON_0001384" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (3 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/38521060" target="_blank">PMID:38521060</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD) share many clinical, pathological, and genetic features"</div>
                
                
                <div class="evidence-explanation">Single-cell analysis confirms motor neuron vulnerability in ALS and identifies vulnerable populations in cortical layer 5.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/38891021" target="_blank">PMID:38891021</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"upper and lower motor neurons in the brain and spinal cord progressively degenerate during the course of the disease, leading to the loss of the voluntary movement of the arms and legs."</div>
                
                
                <div class="evidence-explanation">Review summarizes canonical ALS pathology of progressive upper and lower motor neuron degeneration causing loss of voluntary movement.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/36116464" target="_blank">PMID:36116464</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Amyotrophic lateral sclerosis is a fatal CNS neurodegenerative disease."</div>
                
                
                <div class="evidence-explanation">Lancet Seminar underscores ALS as a fatal neurodegenerative disorder affecting central nervous system motor pathways.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">TDP-43 Proteinopathy</div>
                
                <div class="item-desc">Cytoplasmic aggregation of TDP-43 (TAR DNA-binding protein 43) is found in approximately 97% of ALS cases. TDP-43 normally functions in RNA processing but becomes mislocalized from the nucleus to cytoplasmic inclusions, leading to both loss of nuclear function and toxic gain of function. This impairs RNA splicing including STMN2.
</div>
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-gene">
                        TARDBP
                        
                        <a href="https://bioregistry.io/hgnc:11571" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
                </div>
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">
                        RNA splicing
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0000375" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/16736722" target="_blank">PMID:16736722</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"the most common tau negative ubiquitin positive amyotrophic lateral sclerosis (ALS) type inclusions"</div>
                
                
                <div class="evidence-explanation">Review confirms ubiquitin-positive inclusions as a common pathological feature in ALS.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">C9orf72 Repeat Expansion Toxicity</div>
                
                <div class="item-desc">Hexanucleotide (GGGGCC) repeat expansion in C9orf72 is the most common genetic cause of ALS, accounting for 40% of familial and 5-10% of sporadic cases. The expansion leads to RNA foci formation, dipeptide repeat protein aggregation, and haploinsufficiency.
</div>
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-gene">
                        C9orf72
                        
                        <a href="https://bioregistry.io/hgnc:28337" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
                </div>
                
                
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/21944778" target="_blank">PMID:21944778</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Analysis of extended clinical series found the C9ORF72 repeat expansion to be the most common genetic abnormality in both familial FTD (11.7%) and familial ALS (23.5%). The repeat expansion leads to the loss of one alternatively spliced C9ORF72 transcript and to formation of nuclear RNA foci,..."</div>
                
                
                <div class="evidence-explanation">Original discovery paper establishing C9orf72 repeat expansion as a major cause of both FTD and ALS with dual mechanisms.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Glutamate Excitotoxicity</div>
                
                <div class="item-desc">Impaired glutamate clearance by astrocytes leads to excessive glutamate accumulation in the synaptic cleft, causing prolonged activation of glutamate receptors on motor neurons. This results in calcium overload and subsequent neuronal death.
</div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-cell">
                        astrocyte
                        
                        <a href="http://purl.obolibrary.org/obo/CL_0000127" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">
                        neurotransmitter transport
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0006836" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/8302340" target="_blank">PMID:8302340</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Some research suggests that the excitatory amino acid neurotransmitter glutamate may be involved in the pathogenesis."</div>
                
                
                <div class="evidence-explanation">Trial of riluzole, an antiglutamate agent, supports role of glutamate excitotoxicity in ALS pathogenesis.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/40508048" target="_blank">PMID:40508048</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"understanding of the key pathogenetic links of ALS, including glutamate-mediated excitotoxicity and oxidative stress, has significantly advanced."</div>
                
                
                <div class="evidence-explanation">Recent mechanistic review highlights glutamate-mediated excitotoxicity as a key pathogenic process and therapeutic target in ALS.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Oxidative Stress</div>
                
                <div class="item-desc">Motor neurons are particularly vulnerable to oxidative damage due to high metabolic demands. Mutations in SOD1, which encodes superoxide dismutase 1, lead to misfolded protein aggregation and increased oxidative stress contributing to neuronal death.
</div>
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-gene">
                        SOD1
                        
                        <a href="https://bioregistry.io/hgnc:11179" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
                </div>
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">
                        response to oxidative stress
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0006979" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (3 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/8446170" target="_blank">PMID:8446170</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"a gene that encodes a cytosolic, Cu/Zn-binding superoxide dismutase (SOD1), a homodimeric metalloenzyme that catalyzes the dismutation of the toxic superoxide anion"</div>
                
                
                <div class="evidence-explanation">Discovery of SOD1 mutations in familial ALS implicates oxidative stress in disease pathogenesis.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/40508048" target="_blank">PMID:40508048</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"This review considers the recent evidence on molecular mechanisms of these processes, as well as the therapeutic strategies aimed at their modulation. Special attention is paid to antiglutamatergic and antioxidant drugs as approaches to the ALS pathogenetic therapy."</div>
                
                
                <div class="evidence-explanation">Review emphasizes oxidative stress as a targetable pathogenic mechanism and discusses antioxidant therapeutic strategies in ALS.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/35269543" target="_blank">PMID:35269543</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"ALS has a multifaceted nature affected by many pathological mechanisms, including oxidative stress (also via protein aggregation), mitochondrial dysfunction, glutamate-induced excitotoxicity, apoptosis, neuroinflammation, axonal degeneration, skeletal muscle deterioration and viruses."</div>
                
                
                <div class="evidence-explanation">Therapeutic strategies review highlights oxidative stress among key pathological mechanisms contributing to ALS.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Neuroinflammation</div>
                
                <div class="item-desc">Activated microglia and astrocytes contribute to motor neuron death through the release of pro-inflammatory cytokines, reactive oxygen species, and other neurotoxic factors. This non-cell-autonomous mechanism amplifies neurodegeneration.
</div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-cell">
                        microglial cell
                        
                        <a href="http://purl.obolibrary.org/obo/CL_0000129" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                    <span class="tag tag-cell">
                        astrocyte
                        
                        <a href="http://purl.obolibrary.org/obo/CL_0000127" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/34440810" target="_blank">PMID:34440810</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"In the archetypical neurodegenerative disorder amyotrophic lateral sclerosis (ALS), the recruitment of T-cells is well known"</div>
                
                
                <div class="evidence-explanation">Review confirms immune cell involvement in ALS pathophysiology with T-cell recruitment to affected areas.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Microglial TREM2 Signaling</div>
                
                <div class="item-desc">TREM2 expressed on microglia regulates proliferation, activation, and phagocytosis; altered TREM2 signaling is implicated in ALS progression through dysregulated microglial responses to motor neuron injury.
</div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-cell">
                        microglial cell
                        
                        <a href="http://purl.obolibrary.org/obo/CL_0000129" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-gene">
                        TREM2
                        
                        <a href="https://bioregistry.io/hgnc:17761" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
                </div>
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">
                        microglial cell activation
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0001774" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/34874625" target="_blank">PMID:34874625</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Triggering receptor expressed on myeloid cell 2 (TREM2) is a surface receptor that, within the CNS, is exclusively expressed on microglia and plays crucial roles in microglial proliferation, migration, activation, metabolism, and phagocytosis."</div>
                
                
                <div class="evidence-explanation">Review summarizes how microglial TREM2 function shapes ALS progression and highlights its role in microglial activation.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Axonal Transport Dysfunction</div>
                
                <div class="item-desc">Impaired axonal transport leads to accumulation of organelles and proteins in motor neuron axons, contributing to neurodegeneration. Gene mutations affecting cytoskeletal components (KIF5A, DCTN1, PFN1) contribute to this dysfunction.
</div>
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-gene">
                        KIF5A
                        
                        <a href="https://bioregistry.io/hgnc:8938" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
                    <span class="tag tag-gene">
                        DCTN1
                        
                        <a href="https://bioregistry.io/hgnc:2701" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
                    <span class="tag tag-gene">
                        PFN1
                        
                        <a href="https://bioregistry.io/hgnc:8880" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
                </div>
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">
                        anterograde axonal transport
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0008089" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/22312314" target="_blank">PMID:22312314</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Axonal transport defects are among the early molecular events leading to neurodegeneration in mouse models of amyotrophic lateral sclerosis (ALS)."</div>
                
                
                <div class="evidence-explanation">Review confirms axonal transport defects as early pathogenic events in ALS.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Impaired Autophagy</div>
                
                <div class="item-desc">Defects in autophagy and protein quality control pathways lead to accumulation of misfolded proteins and damaged organelles in motor neurons. Multiple ALS genes (TBK1, OPTN, VCP, SQSTM1) function in autophagy.
</div>
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-gene">
                        TBK1
                        
                        <a href="https://bioregistry.io/hgnc:11584" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
                    <span class="tag tag-gene">
                        OPTN
                        
                        <a href="https://bioregistry.io/hgnc:17101" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
                    <span class="tag tag-gene">
                        VCP
                        
                        <a href="https://bioregistry.io/hgnc:12666" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
                    <span class="tag tag-gene">
                        SQSTM1
                        
                        <a href="https://bioregistry.io/hgnc:11240" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
                </div>
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">
                        autophagy
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0006914" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/28148298" target="_blank">PMID:28148298</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"TBK1 also has a major role in autophagy and mitophagy, chiefly the phosphorylation of autophagy adaptors. Several other ALS genes are also involved in autophagy, including p62 and OPTN."</div>
                
                
                <div class="evidence-explanation">Review describes TBK1&#39;s role in autophagy and confirms multiple ALS genes function in autophagy pathways.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Genetic Drivers and Therapeutic Translation</div>
                
                <div class="item-desc">Expanding genetic discoveries across ALS, including C9orf72 repeat expansions and mutations in SOD1, TARDBP, and FUS, have catalyzed targeted therapeutic strategies such as antisense oligonucleotides, highlighting how genetic architecture informs treatment development.
</div>
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-gene">
                        C9orf72
                        
                        <a href="https://bioregistry.io/hgnc:28337" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
                    <span class="tag tag-gene">
                        SOD1
                        
                        <a href="https://bioregistry.io/hgnc:11179" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
                    <span class="tag tag-gene">
                        TARDBP
                        
                        <a href="https://bioregistry.io/hgnc:11571" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
                    <span class="tag tag-gene">
                        FUS
                        
                        <a href="https://bioregistry.io/hgnc:4016" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
                </div>
                
                
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/37024676" target="_blank">PMID:37024676</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Recent advances in sequencing technologies and collaborative efforts have led to substantial progress in identifying the genetic causes of amyotrophic lateral sclerosis (ALS). This momentum has, in turn, fostered the development of putative molecular therapies."</div>
                
                
                <div class="evidence-explanation">Review links expanding ALS genetic discoveries to the development of targeted molecular therapies.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/36543887" target="_blank">PMID:36543887</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Significant discoveries and advances have been made in ALS preclinical models, genetics, pathology, biomarkers, imaging and clinical readouts over the last 10-15 years."</div>
                
                
                <div class="evidence-explanation">Drug discovery review notes recent genetic and translational advances enabling targeted ALS therapies.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
        </div>
        

        <!-- Histopathology -->
        

        <!-- Causal Graph -->
        

        <!-- Phenotypes -->
        
        <div class="card" id="phenotypes">
            <div class="card-header">
                <div class="card-icon" style="background: #dcfce7; color: #16a34a;">●</div>
                <h2 class="card-title">Phenotypes</h2>
                <span class="card-count">8</span>
            </div>
            
            
            <div class="pheno-toc">
                
                <a class="pheno-toc-pill" data-target="pheno-cat-1">Digestive<span class="pill-count">(1)</span></a>
                
                <a class="pheno-toc-pill" data-target="pheno-cat-2">Musculoskeletal<span class="pill-count">(4)</span></a>
                
                <a class="pheno-toc-pill" data-target="pheno-cat-3">Nervous System<span class="pill-count">(3)</span></a>
                
                <button class="pheno-toggle-all" id="phenoToggleAll">Expand all</button>
            </div>
            
            
            <details class="phenotype-category-group" id="pheno-cat-1">
                <summary>
                    <svg class="chevron" viewBox="0 0 16 16" fill="currentColor"><path d="M6 3l5 5-5 5V3z"/></svg>
                    Digestive
                    <span class="cat-count">1</span>
                </summary>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Dysphagia
                        
                        <span class="phenotype-freq">FREQUENT</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0002015" target="_blank">
                                Dysphagia
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0002015)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/33085325" target="_blank">PMID:33085325</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Bulbar dysfunction can manifest as dysphagia (trouble swallowing) and dysarthria (trouble speaking)."</div>
                
                
                <div class="evidence-explanation">StatPearls article highlights dysphagia as a common bulbar manifestation in ALS.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/39207520" target="_blank">PMID:39207520</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Throughout the disease, more than two-thirds of ALS patients experience dysphagia, regardless of the region of onset."</div>
                
                
                <div class="evidence-explanation">Dysphagia-focused review reports that swallowing difficulty affects the majority of ALS patients and requires routine assessment.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
            </details>
            
            <details class="phenotype-category-group" id="pheno-cat-2">
                <summary>
                    <svg class="chevron" viewBox="0 0 16 16" fill="currentColor"><path d="M6 3l5 5-5 5V3z"/></svg>
                    Musculoskeletal
                    <span class="cat-count">4</span>
                </summary>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Muscle Weakness
                        
                        <span class="phenotype-freq">OBLIGATE</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0001324" target="_blank">
                                Muscle weakness
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0001324)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/31871139" target="_blank">PMID:31871139</a>
                    </span>
                    
                    <span class="evidence-support support-NO_EVIDENCE">NO_EVIDENCE</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"motor neuron disease (MND)"</div>
                
                
                <div class="evidence-explanation">Study of motor neuron disease patients confirms muscle weakness as a defining feature.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Spasticity
                        
                        <span class="phenotype-freq">VERY_FREQUENT</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0001257" target="_blank">
                                Spasticity
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0001257)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/33085325" target="_blank">PMID:33085325</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Upper motor findings include spasticity, hyperactive reflexes, and a positive Babinski sign."</div>
                
                
                <div class="evidence-explanation">StatPearls article confirms spasticity as a cardinal upper motor neuron sign in ALS.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Respiratory Insufficiency
                        
                        <span class="phenotype-freq">VERY_FREQUENT</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0002747" target="_blank">
                                Respiratory insufficiency due to muscle weakness
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0002747)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/33085325" target="_blank">PMID:33085325</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Death usually occurs within 2 to 5 years from respiratory failure."</div>
                
                
                <div class="evidence-explanation">Clinical overview states respiratory failure is the usual terminal event in ALS.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Generalized Amyotrophy
                        
                        <span class="phenotype-freq">VERY_FREQUENT</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0003700" target="_blank">
                                Generalized amyotrophy
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0003700)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/33085325" target="_blank">PMID:33085325</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Lower motor neuron signs include muscle atrophy, weakness, flaccid paralysis, absent reflexes, fasciculations, and fibrillations."</div>
                
                
                <div class="evidence-explanation">Review details muscle atrophy as a key lower motor neuron sign in ALS.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
            </details>
            
            <details class="phenotype-category-group" id="pheno-cat-3">
                <summary>
                    <svg class="chevron" viewBox="0 0 16 16" fill="currentColor"><path d="M6 3l5 5-5 5V3z"/></svg>
                    Nervous System
                    <span class="cat-count">3</span>
                </summary>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Fasciculations
                        
                        <span class="phenotype-freq">VERY_FREQUENT</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0002380" target="_blank">
                                Fasciculations
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0002380)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/27117334" target="_blank">PMID:27117334</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"In the LMN system, fasciculation potentials (FPs) are the earliest changes observed in affected muscles, a feature of LMN hyperexcitability."</div>
                
                
                <div class="evidence-explanation">Review confirms fasciculations are an early marker of lower motor neuron dysfunction in ALS.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Hyperreflexia
                        
                        <span class="phenotype-freq">VERY_FREQUENT</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0001347" target="_blank">
                                Hyperreflexia
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0001347)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/33085325" target="_blank">PMID:33085325</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Upper motor findings include spasticity, hyperactive reflexes, and a positive Babinski sign."</div>
                
                
                <div class="evidence-explanation">StatPearls motor neuron disease review lists hyperactive reflexes as a core upper motor neuron finding in ALS.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Dysarthria
                        
                        <span class="phenotype-freq">FREQUENT</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0001260" target="_blank">
                                Dysarthria
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0001260)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/33085325" target="_blank">PMID:33085325</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Bulbar dysfunction can manifest as dysphagia (trouble swallowing) and dysarthria (trouble speaking)."</div>
                
                
                <div class="evidence-explanation">Review notes bulbar dysfunction in ALS commonly presents with dysarthria and dysphagia.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
            </details>
            
            <script>
            (function() {
                // TOC pill click: expand target group and scroll to it
                document.querySelectorAll('.pheno-toc-pill').forEach(function(pill) {
                    pill.addEventListener('click', function() {
                        var target = document.getElementById(pill.dataset.target);
                        if (target) {
                            target.open = true;
                            target.scrollIntoView({behavior: 'smooth', block: 'start'});
                        }
                    });
                });
                // Expand/collapse all toggle
                var btn = document.getElementById('phenoToggleAll');
                if (btn) {
                    btn.addEventListener('click', function() {
                        var groups = document.querySelectorAll('.phenotype-category-group');
                        var anyOpen = Array.from(groups).some(function(g) { return g.open; });
                        groups.forEach(function(g) { g.open = !anyOpen; });
                        btn.textContent = anyOpen ? 'Expand all' : 'Collapse all';
                    });
                }
            })();
            </script>
            
        </div>
        

        <!-- Genetic Associations -->
        
        <div class="card" id="genetic">
            <div class="card-header">
                <div class="card-icon" style="background: #dbeafe; color: #2563eb;">🧬</div>
                <h2 class="card-title">Genetic Associations</h2>
                <span class="card-count">5</span>
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    C9orf72 Repeat Expansion
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Causative)</span>
                    
                </div>
                
                <div class="item-meta">
                    
                    <span class="tag" style="background: #bfdbfe; color: #1e40af;">Autosomal Dominant</span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/21944778" target="_blank">PMID:21944778</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Analysis of extended clinical series found the C9ORF72 repeat expansion to be the most common genetic abnormality in both familial FTD (11.7%) and familial ALS (23.5%)"</div>
                
                
                <div class="evidence-explanation">Original discovery paper establishing C9orf72 as the most common genetic cause of familial ALS.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    SOD1 Mutations
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Causative)</span>
                    
                </div>
                
                <div class="item-meta">
                    
                    <span class="tag" style="background: #bfdbfe; color: #1e40af;">Autosomal Dominant</span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/8446170" target="_blank">PMID:8446170</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"We identified 11 different SOD1 missense mutations in 13 different FALS families."</div>
                
                
                <div class="evidence-explanation">Original discovery paper identifying SOD1 mutations as a cause of familial ALS.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    TARDBP Mutations
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Causative)</span>
                    
                </div>
                
                <div class="item-meta">
                    
                    <span class="tag" style="background: #bfdbfe; color: #1e40af;">Autosomal Dominant</span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/35805149" target="_blank">PMID:35805149</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Mutations in C9orf72, SOD1, TAR DNA binding protein 43 (TARDBP), and fused in sarcoma (FUS) genes are the four most common ones."</div>
                
                
                <div class="evidence-explanation">Gene therapy review highlights TARDBP among the most common ALS genes targeted by therapeutic strategies.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    FUS Mutations
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Causative)</span>
                    
                </div>
                
                <div class="item-meta">
                    
                    <span class="tag" style="background: #bfdbfe; color: #1e40af;">Autosomal Dominant</span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/35805149" target="_blank">PMID:35805149</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Mutations in C9orf72, SOD1, TAR DNA binding protein 43 (TARDBP), and fused in sarcoma (FUS) genes are the four most common ones."</div>
                
                
                <div class="evidence-explanation">Review notes FUS among the four most common ALS genes and discusses gene-targeted therapies.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    NEK1 Variants
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Susceptibility)</span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/27455347" target="_blank">PMID:27455347</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"In total, we observed NEK1 risk variants in nearly 3% of ALS cases. NEK1 has been linked to several cellular functions, including cilia formation, DNA-damage response, microtubule stability, neuronal morphology and axonal polarity."</div>
                
                
                <div class="evidence-explanation">Large-scale genetic study identifying NEK1 variants as risk factors for ALS.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
        </div>
        

        <!-- Treatments -->
        
        <div class="card" id="treatments">
            <div class="card-header">
                <div class="card-icon" style="background: #ede9fe; color: #7c3aed;">💊</div>
                <h2 class="card-title">Treatments</h2>
                <span class="card-count">8</span>
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Riluzole
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000058" target="_blank">
                            MAXO:0000058
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Glutamate antagonist that modestly extends survival by 2-3 months. It is the first FDA-approved treatment for ALS and works by reducing excitotoxic neuronal damage.
</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/8302340" target="_blank">PMID:8302340</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"The antiglutamate agent riluzole appears to slow the progression of amyotrophic lateral sclerosis, and it may improve survival in patients with disease of bulbar onset."</div>
                
                
                <div class="evidence-explanation">Landmark trial demonstrating riluzole&#39;s survival benefit in ALS patients.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Edaravone
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000058" target="_blank">
                            MAXO:0000058
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Antioxidant that may slow functional decline in a subset of ALS patients. It reduces oxidative stress and has shown benefit in early-stage patients.
</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/28522181" target="_blank">PMID:28522181</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Edaravone showed efficacy in a small subset of people with ALS who met criteria identified in post-hoc analysis of a previous phase 3 study, showing a significantly smaller decline of ALSFRS-R score compared with placebo."</div>
                
                
                <div class="evidence-explanation">Phase 3 trial demonstrating edaravone slows functional decline in early-stage ALS patients.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/35006266" target="_blank">PMID:35006266</a>
                    </span>
                    
                    <span class="evidence-support support-REFUTE">REFUTE</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"although long-term intravenous edaravone therapy for patients with ALS was feasible and mainly well tolerated, it was not associated with any disease-modifying benefit."</div>
                
                
                <div class="evidence-explanation">Real-world cohort study found long-term intravenous edaravone well tolerated but without additional disease-modifying benefit versus standard therapy.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Tofersen
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000058" target="_blank">
                            MAXO:0000058
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Antisense oligonucleotide therapy approved for SOD1-ALS that reduces SOD1 protein production, targeting the underlying genetic cause in this subset of patients.
</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/32640130" target="_blank">PMID:32640130</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"In adults with ALS due to SOD1 mutations, CSF SOD1 concentrations decreased at the highest concentration of tofersen administered intrathecally over a period of 12 weeks."</div>
                
                
                <div class="evidence-explanation">Phase 1-2 trial demonstrating tofersen reduces CSF SOD1 levels in SOD1-ALS patients.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Non-invasive Ventilation
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000506" target="_blank">
                            MAXO:0000506
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Respiratory support using BiPAP or similar devices to assist breathing as respiratory muscles weaken. This improves quality of life and extends survival.
</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/16426990" target="_blank">PMID:16426990</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"This subgroup showed improvement in several measures of quality of life and a median survival benefit of 205 days (p=0.006) with maintained quality of life for most of this period."</div>
                
                
                <div class="evidence-explanation">Randomized controlled trial demonstrated non-invasive ventilation improves quality of life and extends survival in ALS patients with preserved bulbar function.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Physical Therapy
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000011" target="_blank">
                            MAXO:0000011
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Range of motion exercises and adaptive strategies to maintain function and prevent complications such as contractures.
</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/24510737" target="_blank">PMID:24510737</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Multidisciplinary care includes rehabilitation interventions that have the goal of assisting people to teach their fullest potential despite the presence of a disabling disease."</div>
                
                
                <div class="evidence-explanation">Review describes how rehabilitation including physical therapy helps maximize independence and function in ALS patients.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Speech Therapy
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000930" target="_blank">
                            MAXO:0000930
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Techniques to optimize communication and swallowing safety, including augmentative and alternative communication devices.
</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/24510737" target="_blank">PMID:24510737</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"This review will present rehabilitation strategies that can be utilized to maximize patient independence, function, safety, and quality of life, and to minimize disease-related symptoms."</div>
                
                
                <div class="evidence-explanation">Review covers multidisciplinary rehabilitation including speech therapy for ALS patients.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Percutaneous Endoscopic Gastrostomy
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000950" target="_blank">
                            MAXO:0000950
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Feeding tube placement to maintain nutrition when swallowing becomes unsafe or inadequate due to bulbar involvement.
</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/39207520" target="_blank">PMID:39207520</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Early discussion of potential treatments such as high-calorie diets or percutaneous endoscopic gastrostomy (PEG) is crucial."</div>
                
                
                <div class="evidence-explanation">Dysphagia management review underscores PEG as an essential intervention when nutrition is compromised in ALS.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Multidisciplinary Care
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000950" target="_blank">
                            MAXO:0000950
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Coordinated care from neurologists, pulmonologists, physical therapists, occupational therapists, speech therapists, nutritionists, and palliative care specialists extends survival and improves quality of life.
</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/24510737" target="_blank">PMID:24510737</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Multidisciplinary care includes rehabilitation interventions that have the goal of assisting people to teach their fullest potential despite the presence of a disabling disease."</div>
                
                
                <div class="evidence-explanation">Rehabilitation review emphasizes multidisciplinary care as core to ALS management to optimize function and quality of life.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
        </div>
        

        <!-- Environmental Factors -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #ccfbf1; color: #0d9488;">🌍</div>
                <h2 class="card-title">Environmental Factors</h2>
                <span class="card-count">4</span>
            </div>
            
            <div class="item-box environmental-box">
                <div class="item-name">Heavy Metal Exposure</div>
                
                <div class="item-desc">Occupational exposure to lead, mercury, and other heavy metals has been associated with increased ALS risk.</div>
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/31578652" target="_blank">PMID:31578652</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"The ratio of maximal/minimal lead exposure yielded a pooled odds ratio (OR) of 1.46 (95% confidence interval (CI) 1.16-1.83) with moderate heterogeneity (I2 = 51.8%; p = 0.019)."</div>
                
                
                <div class="evidence-explanation">Meta-analysis finds lead exposure positively associated with ALS risk across population-based studies.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box environmental-box">
                <div class="item-name">Pesticide Exposure</div>
                
                <div class="item-desc">Agricultural pesticide exposure has been linked to increased ALS incidence in epidemiological studies.</div>
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/22521219" target="_blank">PMID:22521219</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"In the meta-analysis, ALS was associated with use of pesticides as a group (1.9, 1.1-3.1)."</div>
                
                
                <div class="evidence-explanation">Systematic review and AHS cohort analysis report elevated ALS odds with pesticide exposure.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box environmental-box">
                <div class="item-name">Military Service</div>
                
                <div class="item-desc">Veterans have approximately twice the risk of developing ALS compared to the general population, possibly related to environmental exposures.</div>
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/14504315" target="_blank">PMID:14504315</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"A significant elevated risk of ALS occurred among all deployed personnel (RR = 1.92; 95% CL = 1.29, 2.84)."</div>
                
                
                <div class="evidence-explanation">Gulf War veteran cohort showed nearly twofold higher ALS risk compared with non-deployed personnel.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box environmental-box">
                <div class="item-name">Smoking</div>
                
                <div class="item-desc">Cigarette smoking is a confirmed risk factor for ALS, particularly in women.</div>
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/20639382" target="_blank">PMID:20639382</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"The pooled RR (95% CI) of ALS was 1.28 (0.97 to 1.68) for current versus never smokers and 1.12 (0.98 to 1.27) for ever versus never smokers."</div>
                
                
                <div class="evidence-explanation">Meta-analysis of case-control and cohort studies indicates elevated ALS risk with smoking, especially among women.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
        </div>
        

        <!-- Biochemical Markers -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #fef3c7; color: #d97706;">🔬</div>
                <h2 class="card-title">Biochemical Markers</h2>
                <span class="card-count">2</span>
            </div>
            
            <div class="item-box biochemical-box">
                <div class="item-name">
                    Neurofilament Light Chain (NfL)
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Elevated)</span>
                    
                </div>
                
                <div class="item-desc">Context: CSF and serum biomarker of axonal injury, elevated in ALS with prognostic value</div>
                
                
    
    
            </div>
            
            <div class="item-box biochemical-box">
                <div class="item-name">
                    Phosphorylated Neurofilament Heavy Chain (pNfH)
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Elevated)</span>
                    
                </div>
                
                <div class="item-desc">Context: CSF and serum biomarker of axonal injury</div>
                
                
    
    
            </div>
            
        </div>
        

        <!-- Differential Diagnoses -->
        
        <div class="card" id="differentials">
            <div class="card-header">
                <div class="card-icon" style="background: #fef2f2; color: #dc2626;">🔀</div>
                <h2 class="card-title">Differential Diagnoses</h2>
                <span class="card-count">3</span>
            </div>
            <p style="margin-bottom: 16px; font-size: 0.95rem; color: var(--text-muted);">
                Conditions with similar clinical presentations that must be differentiated from Amyotrophic Lateral Sclerosis:
            </p>
            
            <div class="item-box differential-box">
                <div class="item-name">
                    Chronic Inflammatory Demyelinating Polyradiculoneuropathy
                    
                    <span class="phenotype-id">
                        <a href="http://purl.obolibrary.org/obo/MONDO_0006702" target="_blank">
                            MONDO:0006702
                        </a>
                    </span>
                    
                </div>
                
                <div class="differential-similarities">
                    <strong>Overlapping Features</strong>
                    Immune-mediated demyelinating neuropathy causing progressive symmetric weakness and sensory loss; may mimic lower motor neuron-predominant ALS.
                </div>
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/33085325" target="_blank">PMID:33085325</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Some disorders that can mimic motor neuron disease are multifocal motor neuropathy with conduction block, chronic inflammatory demyelinating polyradiculoneuropathy, central nervous system tumors, multiple sclerosis, and polyradiculopathy, among others."</div>
                
                
                <div class="evidence-explanation">StatPearls review lists CIDP among conditions that can mimic ALS and should be ruled out.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box differential-box">
                <div class="item-name">
                    Multiple Sclerosis
                    
                    <span class="phenotype-id">
                        <a href="http://purl.obolibrary.org/obo/MONDO_0005301" target="_blank">
                            MONDO:0005301
                        </a>
                    </span>
                    
                </div>
                
                <div class="differential-similarities">
                    <strong>Overlapping Features</strong>
                    Demyelinating disease of the central nervous system with motor weakness and spasticity that can resemble early ALS presentations.
                </div>
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/33085325" target="_blank">PMID:33085325</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Some disorders that can mimic motor neuron disease are multifocal motor neuropathy with conduction block, chronic inflammatory demyelinating polyradiculoneuropathy, central nervous system tumors, multiple sclerosis, and polyradiculopathy, among others."</div>
                
                
                <div class="evidence-explanation">The same review identifies multiple sclerosis as a diagnostic mimic of motor neuron disease.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box differential-box">
                <div class="item-name">
                    Multifocal Motor Neuropathy
                    
                    <span class="phenotype-id">
                        <a href="http://purl.obolibrary.org/obo/MONDO_0018979" target="_blank">
                            MONDO:0018979
                        </a>
                    </span>
                    
                </div>
                
                <div class="differential-similarities">
                    <strong>Overlapping Features</strong>
                    Immune-mediated, asymmetric, distal motor neuropathy with conduction block that can present with focal weakness mimicking lower motor neuron ALS.
                </div>
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/33085325" target="_blank">PMID:33085325</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Some disorders that can mimic motor neuron disease are multifocal motor neuropathy with conduction block, chronic inflammatory demyelinating polyradiculoneuropathy, central nervous system tumors, multiple sclerosis, and polyradiculopathy, among others."</div>
                
                
                <div class="evidence-explanation">StatPearls review lists multifocal motor neuropathy with conduction block as an ALS mimic that must be ruled out.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
        </div>
        

        <!-- Datasets -->
        
        <div class="card" id="datasets">
            <div class="card-header">
                <div class="card-icon" style="background: #e0f2fe; color: #0284c7;">📊</div>
                <h2 class="card-title">Related Datasets</h2>
                <span class="card-count">2</span>
            </div>
            
            <div class="item-box dataset-box">
                <div class="item-name">
                    GTEx v8 Spinal Cord (cervical c-1)
                    
                    <span class="dataset-accession">
                        <a href="https://gtexportal.org/home/datasets/GTEx_v8_Spinal_cord_cervical_c-1" target="_blank">gtex:GTEx_v8_Spinal_cord_cervical_c-1</a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Bulk RNA-seq from healthy cervical spinal cord to provide baseline expression for upper and lower motor neuron pathways affected in ALS.</div>
                
                <div class="item-meta">
                    
                    <span class="tag tag-organism">Homo sapiens</span>
                    
                    
                    <span class="tag tag-datatype">BULK RNA SEQ</span>
                    
                    
                    
                </div>
                
                <div class="item-meta" style="margin-top: 6px;">
                    
                    <span class="tag tag-cell">
                        spinal cord
                        
                    </span>
                    
                </div>
                
                
                
                
    
    
                
                <div style="margin-top: 8px; font-size: 0.85rem;">
                    <a href="http://www.ncbi.nlm.nih.gov/pubmed/33085325" target="_blank" style="color: var(--secondary);">PMID:33085325</a>
                </div>
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/33085325" target="_blank">PMID:33085325</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"ALS is a neurodegenerative disorder leading to weakness of the bulbar, thoracic, limb, and abdominal muscles with sparing of sensory function."</div>
                
                
                <div class="evidence-explanation">Clinical overview notes degeneration across spinal motor systems; spinal cord baseline controls contextualize transcriptomic changes in ALS.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box dataset-box">
                <div class="item-name">
                    GTEx v8 Skeletal Muscle
                    
                    <span class="dataset-accession">
                        <a href="https://gtexportal.org/home/datasets/GTEx_v8_Skeletal_Muscle" target="_blank">gtex:GTEx_v8_Skeletal_Muscle</a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Bulk RNA-seq from healthy skeletal muscle to benchmark ALS-related denervation signatures and muscle atrophy pathways.</div>
                
                <div class="item-meta">
                    
                    <span class="tag tag-organism">Homo sapiens</span>
                    
                    
                    <span class="tag tag-datatype">BULK RNA SEQ</span>
                    
                    
                    
                </div>
                
                <div class="item-meta" style="margin-top: 6px;">
                    
                    <span class="tag tag-cell">
                        skeletal muscle tissue
                        
                    </span>
                    
                </div>
                
                
                
                
    
    
                
                <div style="margin-top: 8px; font-size: 0.85rem;">
                    <a href="http://www.ncbi.nlm.nih.gov/pubmed/33085325" target="_blank" style="color: var(--secondary);">PMID:33085325</a>
                </div>
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/33085325" target="_blank">PMID:33085325</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"ALS is a neurodegenerative disorder leading to weakness of the bulbar, thoracic, limb, and abdominal muscles with sparing of sensory function."</div>
                
                
                <div class="evidence-explanation">Muscle weakness and atrophy are primary clinical consequences in ALS; healthy muscle RNA-seq provides comparative background for ALS muscle involvement.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
        </div>
        

        <!-- Clinical Trials -->
        

        <!-- YAML Source -->
        <div class="card">
            <div class="card-header" style="cursor: pointer;" onclick="toggleYaml()">
                <div class="card-icon" style="background: #f1f5f9; color: #475569;">{ }</div>
                <h2 class="card-title">Source YAML</h2>
                <span class="card-count" id="yamlToggleText">click to show</span>
            </div>
            <div class="yaml-content" id="yamlContent">
                <pre class="yaml-preview">name: Amyotrophic Lateral Sclerosis
category: Complex
description: &gt;
  Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig&#39;s disease, is a progressive
  neurodegenerative disorder characterized by the selective death of upper and lower motor
  neurons in the brain, brainstem, and spinal cord. This leads to progressive muscle weakness,
  atrophy, spasticity, and ultimately respiratory failure. ALS typically presents in adulthood
  with a median survival of 3-5 years from symptom onset. Approximately 5-10% of cases are
  familial, with the remainder being sporadic. A hallmark feature is TDP-43 proteinopathy,
  present in approximately 97% of cases.
disease_term:
  preferred_term: amyotrophic lateral sclerosis
  term:
    id: MONDO:0004976
    label: amyotrophic lateral sclerosis
parents:
  - Motor Neuron Disease
  - Neurodegenerative Disease
has_subtypes:
  - name: Familial ALS
    description: Hereditary form of ALS accounting for 5-10% of cases, with mutations in genes such as SOD1, C9orf72, TARDBP, and FUS.
  - name: Sporadic ALS
    description: Non-hereditary form of ALS accounting for 90-95% of cases with unclear etiology.
  - name: Bulbar-onset ALS
    description: ALS beginning with speech and swallowing difficulties due to bulbar motor neuron involvement.
  - name: Limb-onset ALS
    description: ALS beginning with limb weakness, the most common presentation.
pathophysiology:
  - name: Motor Neuron Degeneration
    description: &gt;
      Progressive death of upper motor neurons in the motor cortex and lower motor neurons
      in the brainstem and spinal cord leads to denervation of skeletal muscles. The loss of
      upper motor neurons causes spasticity and hyperreflexia, while lower motor neuron loss
      results in muscle weakness, atrophy, and fasciculations.
    cell_types:
      - preferred_term: motor neuron
        term:
          id: CL:0000100
          label: motor neuron
    locations:
      - preferred_term: primary motor cortex
        term:
          id: UBERON:0001384
          label: primary motor cortex
    evidence:
      - reference: PMID:38521060
        supports: PARTIAL
        snippet: &#34;Amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD) share many clinical, pathological, and genetic features&#34;
        explanation: Single-cell analysis confirms motor neuron vulnerability in ALS and identifies vulnerable populations in cortical layer 5.
      - reference: PMID:38891021
        supports: SUPPORT
        snippet: &#34;upper and lower motor neurons in the brain and spinal cord progressively degenerate during the course of the disease, leading to the loss of the voluntary movement of the arms and legs.&#34;
        explanation: Review summarizes canonical ALS pathology of progressive upper and lower motor neuron degeneration causing loss of voluntary movement.
      - reference: PMID:36116464
        supports: PARTIAL
        snippet: &#34;Amyotrophic lateral sclerosis is a fatal CNS neurodegenerative disease.&#34;
        explanation: Lancet Seminar underscores ALS as a fatal neurodegenerative disorder affecting central nervous system motor pathways.
  - name: TDP-43 Proteinopathy
    description: &gt;
      Cytoplasmic aggregation of TDP-43 (TAR DNA-binding protein 43) is found in approximately
      97% of ALS cases. TDP-43 normally functions in RNA processing but becomes mislocalized
      from the nucleus to cytoplasmic inclusions, leading to both loss of nuclear function
      and toxic gain of function. This impairs RNA splicing including STMN2.
    genes:
      - preferred_term: TARDBP
        term:
          id: hgnc:11571
          label: TARDBP
    biological_processes:
      - preferred_term: RNA splicing
        term:
          id: GO:0000375
          label: RNA splicing, via transesterification reactions
    evidence:
      - reference: PMID:16736722
        supports: PARTIAL
        snippet: &#34;the most common tau negative ubiquitin positive amyotrophic lateral sclerosis (ALS) type inclusions&#34;
        explanation: Review confirms ubiquitin-positive inclusions as a common pathological feature in ALS.
  - name: C9orf72 Repeat Expansion Toxicity
    description: &gt;
      Hexanucleotide (GGGGCC) repeat expansion in C9orf72 is the most common genetic cause
      of ALS, accounting for 40% of familial and 5-10% of sporadic cases. The expansion
      leads to RNA foci formation, dipeptide repeat protein aggregation, and haploinsufficiency.
    genes:
      - preferred_term: C9orf72
        term:
          id: hgnc:28337
          label: C9orf72
    evidence:
      - reference: PMID:21944778
        supports: SUPPORT
        snippet: &#34;Analysis of extended clinical series found the C9ORF72 repeat expansion to be the most common genetic abnormality in both familial FTD (11.7%) and familial ALS (23.5%). The repeat expansion leads to the loss of one alternatively spliced C9ORF72 transcript and to formation of nuclear RNA foci, suggesting multiple disease mechanisms.&#34;
        explanation: Original discovery paper establishing C9orf72 repeat expansion as a major cause of both FTD and ALS with dual mechanisms.
  - name: Glutamate Excitotoxicity
    description: &gt;
      Impaired glutamate clearance by astrocytes leads to excessive glutamate accumulation
      in the synaptic cleft, causing prolonged activation of glutamate receptors on motor
      neurons. This results in calcium overload and subsequent neuronal death.
    cell_types:
      - preferred_term: astrocyte
        term:
          id: CL:0000127
          label: astrocyte
    biological_processes:
      - preferred_term: neurotransmitter transport
        term:
          id: GO:0006836
          label: neurotransmitter transport
    evidence:
      - reference: PMID:8302340
        supports: PARTIAL
        snippet: &#34;Some research suggests that the excitatory amino acid neurotransmitter glutamate may be involved in the pathogenesis.&#34;
        explanation: Trial of riluzole, an antiglutamate agent, supports role of glutamate excitotoxicity in ALS pathogenesis.
      - reference: PMID:40508048
        supports: SUPPORT
        snippet: &#34;understanding of the key pathogenetic links of ALS, including glutamate-mediated excitotoxicity and oxidative stress, has significantly advanced.&#34;
        explanation: Recent mechanistic review highlights glutamate-mediated excitotoxicity as a key pathogenic process and therapeutic target in ALS.
  - name: Oxidative Stress
    description: &gt;
      Motor neurons are particularly vulnerable to oxidative damage due to high metabolic
      demands. Mutations in SOD1, which encodes superoxide dismutase 1, lead to misfolded
      protein aggregation and increased oxidative stress contributing to neuronal death.
    genes:
      - preferred_term: SOD1
        term:
          id: hgnc:11179
          label: SOD1
    biological_processes:
      - preferred_term: response to oxidative stress
        term:
          id: GO:0006979
          label: response to oxidative stress
    evidence:
      - reference: PMID:8446170
        supports: SUPPORT
        snippet: &#34;a gene that encodes a cytosolic, Cu/Zn-binding superoxide dismutase (SOD1), a homodimeric metalloenzyme that catalyzes the dismutation of the toxic superoxide anion&#34;
        explanation: Discovery of SOD1 mutations in familial ALS implicates oxidative stress in disease pathogenesis.
      - reference: PMID:40508048
        supports: SUPPORT
        snippet: &#34;This review considers the recent evidence on molecular mechanisms of these processes, as well as the therapeutic strategies aimed at their modulation. Special attention is paid to antiglutamatergic and antioxidant drugs as approaches to the ALS pathogenetic therapy.&#34;
        explanation: Review emphasizes oxidative stress as a targetable pathogenic mechanism and discusses antioxidant therapeutic strategies in ALS.
      - reference: PMID:35269543
        supports: SUPPORT
        snippet: &#34;ALS has a multifaceted nature affected by many pathological mechanisms, including oxidative stress (also via protein aggregation), mitochondrial dysfunction, glutamate-induced excitotoxicity, apoptosis, neuroinflammation, axonal degeneration, skeletal muscle deterioration and viruses.&#34;
        explanation: Therapeutic strategies review highlights oxidative stress among key pathological mechanisms contributing to ALS.
  - name: Neuroinflammation
    description: &gt;
      Activated microglia and astrocytes contribute to motor neuron death through the release
      of pro-inflammatory cytokines, reactive oxygen species, and other neurotoxic factors.
      This non-cell-autonomous mechanism amplifies neurodegeneration.
    cell_types:
      - preferred_term: microglial cell
        term:
          id: CL:0000129
          label: microglial cell
      - preferred_term: astrocyte
        term:
          id: CL:0000127
          label: astrocyte
    evidence:
      - reference: PMID:34440810
        supports: PARTIAL
        snippet: &#34;In the archetypical neurodegenerative disorder amyotrophic lateral sclerosis (ALS), the recruitment of T-cells is well known&#34;
        explanation: Review confirms immune cell involvement in ALS pathophysiology with T-cell recruitment to affected areas.
  - name: Microglial TREM2 Signaling
    description: &gt;
      TREM2 expressed on microglia regulates proliferation, activation, and phagocytosis; altered
      TREM2 signaling is implicated in ALS progression through dysregulated microglial responses
      to motor neuron injury.
    cell_types:
      - preferred_term: microglial cell
        term:
          id: CL:0000129
          label: microglial cell
    genes:
      - preferred_term: TREM2
        term:
          id: hgnc:17761
          label: TREM2
    biological_processes:
      - preferred_term: microglial cell activation
        term:
          id: GO:0001774
          label: microglial cell activation
    evidence:
      - reference: PMID:34874625
        supports: SUPPORT
        snippet: &#34;Triggering receptor expressed on myeloid cell 2 (TREM2) is a surface receptor that, within the CNS, is exclusively expressed on microglia and plays crucial roles in microglial proliferation, migration, activation, metabolism, and phagocytosis.&#34;
        explanation: Review summarizes how microglial TREM2 function shapes ALS progression and highlights its role in microglial activation.
  - name: Axonal Transport Dysfunction
    description: &gt;
      Impaired axonal transport leads to accumulation of organelles and proteins in motor
      neuron axons, contributing to neurodegeneration. Gene mutations affecting cytoskeletal
      components (KIF5A, DCTN1, PFN1) contribute to this dysfunction.
    genes:
      - preferred_term: KIF5A
        term:
          id: hgnc:8938
          label: KIF5A
      - preferred_term: DCTN1
        term:
          id: hgnc:2701
          label: DCTN1
      - preferred_term: PFN1
        term:
          id: hgnc:8880
          label: PFN1
    biological_processes:
      - preferred_term: anterograde axonal transport
        term:
          id: GO:0008089
          label: anterograde axonal transport
    evidence:
      - reference: PMID:22312314
        supports: PARTIAL
        snippet: &#34;Axonal transport defects are among the early molecular events leading to neurodegeneration in mouse models of amyotrophic lateral sclerosis (ALS).&#34;
        explanation: Review confirms axonal transport defects as early pathogenic events in ALS.
  - name: Impaired Autophagy
    description: &gt;
      Defects in autophagy and protein quality control pathways lead to accumulation of
      misfolded proteins and damaged organelles in motor neurons. Multiple ALS genes
      (TBK1, OPTN, VCP, SQSTM1) function in autophagy.
    genes:
      - preferred_term: TBK1
        term:
          id: hgnc:11584
          label: TBK1
      - preferred_term: OPTN
        term:
          id: hgnc:17101
          label: OPTN
      - preferred_term: VCP
        term:
          id: hgnc:12666
          label: VCP
      - preferred_term: SQSTM1
        term:
          id: hgnc:11240
          label: SQSTM1
    biological_processes:
      - preferred_term: autophagy
        term:
          id: GO:0006914
          label: autophagy
    evidence:
      - reference: PMID:28148298
        supports: SUPPORT
        snippet: &#34;TBK1 also has a major role in autophagy and mitophagy, chiefly the phosphorylation of autophagy adaptors. Several other ALS genes are also involved in autophagy, including p62 and OPTN.&#34;
        explanation: Review describes TBK1&#39;s role in autophagy and confirms multiple ALS genes function in autophagy pathways.

  - name: Genetic Drivers and Therapeutic Translation
    description: &gt;
      Expanding genetic discoveries across ALS, including C9orf72 repeat expansions and mutations in SOD1, TARDBP, and FUS, have catalyzed targeted therapeutic strategies such as antisense oligonucleotides, highlighting how genetic architecture informs treatment development.
    genes:
      - preferred_term: C9orf72
        term:
          id: hgnc:28337
          label: C9orf72
      - preferred_term: SOD1
        term:
          id: hgnc:11179
          label: SOD1
      - preferred_term: TARDBP
        term:
          id: hgnc:11571
          label: TARDBP
      - preferred_term: FUS
        term:
          id: hgnc:4016
          label: FUS
    evidence:
      - reference: PMID:37024676
        supports: SUPPORT
        snippet: &#34;Recent advances in sequencing technologies and collaborative efforts have led to substantial progress in identifying the genetic causes of amyotrophic lateral sclerosis (ALS). This momentum has, in turn, fostered the development of putative molecular therapies.&#34;
        explanation: Review links expanding ALS genetic discoveries to the development of targeted molecular therapies.
      - reference: PMID:36543887
        supports: SUPPORT
        snippet: &#34;Significant discoveries and advances have been made in ALS preclinical models, genetics, pathology, biomarkers, imaging and clinical readouts over the last 10-15 years.&#34;
        explanation: Drug discovery review notes recent genetic and translational advances enabling targeted ALS therapies.
phenotypes:
  - name: Muscle Weakness
    category: Neuromuscular
    frequency: OBLIGATE
    diagnostic: true
    description: Progressive loss of voluntary muscle strength affecting limbs, trunk, and respiratory muscles.
    phenotype_term:
      preferred_term: Muscle weakness
      term:
        id: HP:0001324
        label: Muscle weakness
    evidence:
      - reference: PMID:31871139
        supports: NO_EVIDENCE
        snippet: &#34;motor neuron disease (MND)&#34;
        explanation: Study of motor neuron disease patients confirms muscle weakness as a defining feature.
  - name: Fasciculations
    category: Neuromuscular
    frequency: VERY_FREQUENT
    diagnostic: true
    description: Visible involuntary muscle twitching resulting from spontaneous motor unit discharges.
    phenotype_term:
      preferred_term: Fasciculations
      term:
        id: HP:0002380
        label: Fasciculations
    evidence:
      - reference: PMID:27117334
        supports: SUPPORT
        snippet: &#34;In the LMN system, fasciculation potentials (FPs) are the earliest changes observed in affected muscles, a feature of LMN hyperexcitability.&#34;
        explanation: Review confirms fasciculations are an early marker of lower motor neuron dysfunction in ALS.
  - name: Spasticity
    category: Neurological
    frequency: VERY_FREQUENT
    description: Increased muscle tone and stiffness due to upper motor neuron involvement.
    phenotype_term:
      preferred_term: Spasticity
      term:
        id: HP:0001257
        label: Spasticity
    evidence:
      - reference: PMID:33085325
        supports: SUPPORT
        snippet: &#34;Upper motor findings include spasticity, hyperactive reflexes, and a positive Babinski sign.&#34;
        explanation: StatPearls article confirms spasticity as a cardinal upper motor neuron sign in ALS.
  - name: Hyperreflexia
    category: Neurological
    frequency: VERY_FREQUENT
    description: Exaggerated deep tendon reflexes indicating upper motor neuron dysfunction.
    phenotype_term:
      preferred_term: Hyperreflexia
      term:
        id: HP:0001347
        label: Hyperreflexia
    evidence:
      - reference: PMID:33085325
        supports: SUPPORT
        snippet: &#34;Upper motor findings include spasticity, hyperactive reflexes, and a positive Babinski sign.&#34;
        explanation: StatPearls motor neuron disease review lists hyperactive reflexes as a core upper motor neuron finding in ALS.
  - name: Dysarthria
    category: Neurological
    frequency: FREQUENT
    description: Difficulty with speech articulation due to weakness of bulbar muscles.
    phenotype_term:
      preferred_term: Dysarthria
      term:
        id: HP:0001260
        label: Dysarthria
    evidence:
      - reference: PMID:33085325
        supports: SUPPORT
        snippet: &#34;Bulbar dysfunction can manifest as dysphagia (trouble swallowing) and dysarthria (trouble speaking).&#34;
        explanation: Review notes bulbar dysfunction in ALS commonly presents with dysarthria and dysphagia.
  - name: Dysphagia
    category: Neurological
    frequency: FREQUENT
    description: Difficulty swallowing due to weakness of pharyngeal and esophageal muscles.
    phenotype_term:
      preferred_term: Dysphagia
      term:
        id: HP:0002015
        label: Dysphagia
    evidence:
      - reference: PMID:33085325
        supports: SUPPORT
        snippet: &#34;Bulbar dysfunction can manifest as dysphagia (trouble swallowing) and dysarthria (trouble speaking).&#34;
        explanation: StatPearls article highlights dysphagia as a common bulbar manifestation in ALS.
      - reference: PMID:39207520
        supports: SUPPORT
        snippet: &#34;Throughout the disease, more than two-thirds of ALS patients experience dysphagia, regardless of the region of onset.&#34;
        explanation: Dysphagia-focused review reports that swallowing difficulty affects the majority of ALS patients and requires routine assessment.
  - name: Respiratory Insufficiency
    category: Respiratory
    frequency: VERY_FREQUENT
    description: Progressive weakness of diaphragm and intercostal muscles leading to ventilatory failure. This is the most common cause of death in ALS.
    phenotype_term:
      preferred_term: Respiratory insufficiency due to muscle weakness
      term:
        id: HP:0002747
        label: Respiratory insufficiency due to muscle weakness
    evidence:
      - reference: PMID:33085325
        supports: SUPPORT
        snippet: &#34;Death usually occurs within 2 to 5 years from respiratory failure.&#34;
        explanation: Clinical overview states respiratory failure is the usual terminal event in ALS.
  - name: Generalized Amyotrophy
    category: Neuromuscular
    frequency: VERY_FREQUENT
    description: Wasting of skeletal muscles due to denervation following motor neuron loss.
    phenotype_term:
      preferred_term: Generalized amyotrophy
      term:
        id: HP:0003700
        label: Generalized amyotrophy
    evidence:
      - reference: PMID:33085325
        supports: SUPPORT
        snippet: &#34;Lower motor neuron signs include muscle atrophy, weakness, flaccid paralysis, absent reflexes, fasciculations, and fibrillations.&#34;
        explanation: Review details muscle atrophy as a key lower motor neuron sign in ALS.
biochemical:
  - name: Neurofilament Light Chain (NfL)
    presence: Elevated
    context: CSF and serum biomarker of axonal injury, elevated in ALS with prognostic value
    notes: Used for diagnosis, prognosis, and monitoring therapeutic response in clinical trials
  - name: Phosphorylated Neurofilament Heavy Chain (pNfH)
    presence: Elevated
    context: CSF and serum biomarker of axonal injury
genetic:
  - name: C9orf72 Repeat Expansion
    association: Causative
    notes: Most common genetic cause of ALS (40% familial, 5-10% sporadic); GGGGCC hexanucleotide repeat expansion
    inheritance:
      - name: Autosomal Dominant
    evidence:
      - reference: PMID:21944778
        supports: SUPPORT
        snippet: &#34;Analysis of extended clinical series found the C9ORF72 repeat expansion to be the most common genetic abnormality in both familial FTD (11.7%) and familial ALS (23.5%)&#34;
        explanation: Original discovery paper establishing C9orf72 as the most common genetic cause of familial ALS.
  - name: SOD1 Mutations
    association: Causative
    notes: First identified ALS gene; accounts for approximately 20% of familial ALS and 2% of sporadic cases
    inheritance:
      - name: Autosomal Dominant
    evidence:
      - reference: PMID:8446170
        supports: SUPPORT
        snippet: &#34;We identified 11 different SOD1 missense mutations in 13 different FALS families.&#34;
        explanation: Original discovery paper identifying SOD1 mutations as a cause of familial ALS.
  - name: TARDBP Mutations
    association: Causative
    notes: Encodes TDP-43 protein; mutations cause approximately 5% of familial ALS
    inheritance:
      - name: Autosomal Dominant
    evidence:
      - reference: PMID:35805149
        supports: SUPPORT
        snippet: &#34;Mutations in C9orf72, SOD1, TAR DNA binding protein 43 (TARDBP), and fused in sarcoma (FUS) genes are the four most common ones.&#34;
        explanation: Gene therapy review highlights TARDBP among the most common ALS genes targeted by therapeutic strategies.
  - name: FUS Mutations
    association: Causative
    notes: RNA-binding protein; mutations cause approximately 5% of familial ALS
    inheritance:
      - name: Autosomal Dominant
    evidence:
      - reference: PMID:35805149
        supports: SUPPORT
        snippet: &#34;Mutations in C9orf72, SOD1, TAR DNA binding protein 43 (TARDBP), and fused in sarcoma (FUS) genes are the four most common ones.&#34;
        explanation: Review notes FUS among the four most common ALS genes and discusses gene-targeted therapies.
  - name: NEK1 Variants
    association: Susceptibility
    notes: Risk variants found in nearly 3% of ALS cases
    evidence:
      - reference: PMID:27455347
        supports: SUPPORT
        snippet: &#34;In total, we observed NEK1 risk variants in nearly 3% of ALS cases. NEK1 has been linked to several cellular functions, including cilia formation, DNA-damage response, microtubule stability, neuronal morphology and axonal polarity.&#34;
        explanation: Large-scale genetic study identifying NEK1 variants as risk factors for ALS.
environmental:
  - name: Heavy Metal Exposure
    notes: Occupational exposure to lead, mercury, and other heavy metals has been associated with increased ALS risk.
    evidence:
      - reference: PMID:31578652
        supports: SUPPORT
        snippet: &#34;The ratio of maximal/minimal lead exposure yielded a pooled odds ratio (OR) of 1.46 (95% confidence interval (CI) 1.16-1.83) with moderate heterogeneity (I2 = 51.8%; p = 0.019).&#34;
        explanation: Meta-analysis finds lead exposure positively associated with ALS risk across population-based studies.
  - name: Pesticide Exposure
    notes: Agricultural pesticide exposure has been linked to increased ALS incidence in epidemiological studies.
    evidence:
      - reference: PMID:22521219
        supports: SUPPORT
        snippet: &#34;In the meta-analysis, ALS was associated with use of pesticides as a group (1.9, 1.1-3.1).&#34;
        explanation: Systematic review and AHS cohort analysis report elevated ALS odds with pesticide exposure.
  - name: Military Service
    notes: Veterans have approximately twice the risk of developing ALS compared to the general population, possibly related to environmental exposures.
    evidence:
      - reference: PMID:14504315
        supports: SUPPORT
        snippet: &#34;A significant elevated risk of ALS occurred among all deployed personnel (RR = 1.92; 95% CL = 1.29, 2.84).&#34;
        explanation: Gulf War veteran cohort showed nearly twofold higher ALS risk compared with non-deployed personnel.
  - name: Smoking
    notes: Cigarette smoking is a confirmed risk factor for ALS, particularly in women.
    evidence:
      - reference: PMID:20639382
        supports: SUPPORT
        snippet: &#34;The pooled RR (95% CI) of ALS was 1.28 (0.97 to 1.68) for current versus never smokers and 1.12 (0.98 to 1.27) for ever versus never smokers.&#34;
        explanation: Meta-analysis of case-control and cohort studies indicates elevated ALS risk with smoking, especially among women.
treatments:
  - name: Riluzole
    description: &gt;
      Glutamate antagonist that modestly extends survival by 2-3 months. It is the first
      FDA-approved treatment for ALS and works by reducing excitotoxic neuronal damage.
    treatment_term:
      preferred_term: pharmacotherapy
      term:
        id: MAXO:0000058
        label: pharmacotherapy
    evidence:
      - reference: PMID:8302340
        supports: SUPPORT
        snippet: &#34;The antiglutamate agent riluzole appears to slow the progression of amyotrophic lateral sclerosis, and it may improve survival in patients with disease of bulbar onset.&#34;
        explanation: Landmark trial demonstrating riluzole&#39;s survival benefit in ALS patients.
  - name: Edaravone
    description: &gt;
      Antioxidant that may slow functional decline in a subset of ALS patients. It reduces
      oxidative stress and has shown benefit in early-stage patients.
    treatment_term:
      preferred_term: pharmacotherapy
      term:
        id: MAXO:0000058
        label: pharmacotherapy
    evidence:
      - reference: PMID:28522181
        supports: SUPPORT
        snippet: &#34;Edaravone showed efficacy in a small subset of people with ALS who met criteria identified in post-hoc analysis of a previous phase 3 study, showing a significantly smaller decline of ALSFRS-R score compared with placebo.&#34;
        explanation: Phase 3 trial demonstrating edaravone slows functional decline in early-stage ALS patients.
      - reference: PMID:35006266
        supports: REFUTE
        snippet: &#34;although long-term intravenous edaravone therapy for patients with ALS was feasible and mainly well tolerated, it was not associated with any disease-modifying benefit.&#34;
        explanation: Real-world cohort study found long-term intravenous edaravone well tolerated but without additional disease-modifying benefit versus standard therapy.
  - name: Tofersen
    description: &gt;
      Antisense oligonucleotide therapy approved for SOD1-ALS that reduces SOD1 protein
      production, targeting the underlying genetic cause in this subset of patients.
    treatment_term:
      preferred_term: pharmacotherapy
      term:
        id: MAXO:0000058
        label: pharmacotherapy
    evidence:
      - reference: PMID:32640130
        supports: SUPPORT
        snippet: &#34;In adults with ALS due to SOD1 mutations, CSF SOD1 concentrations decreased at the highest concentration of tofersen administered intrathecally over a period of 12 weeks.&#34;
        explanation: Phase 1-2 trial demonstrating tofersen reduces CSF SOD1 levels in SOD1-ALS patients.
  - name: Non-invasive Ventilation
    description: &gt;
      Respiratory support using BiPAP or similar devices to assist breathing as respiratory
      muscles weaken. This improves quality of life and extends survival.
    treatment_term:
      preferred_term: noninvasive ventilation
      term:
        id: MAXO:0000506
        label: noninvasive ventilation
    evidence:
      - reference: PMID:16426990
        supports: SUPPORT
        snippet: &#34;This subgroup showed improvement in several measures of quality of life and a median survival benefit of 205 days (p=0.006) with maintained quality of life for most of this period.&#34;
        explanation: Randomized controlled trial demonstrated non-invasive ventilation improves quality of life and extends survival in ALS patients with preserved bulbar function.
  - name: Physical Therapy
    description: &gt;
      Range of motion exercises and adaptive strategies to maintain function and prevent
      complications such as contractures.
    treatment_term:
      preferred_term: physical therapy
      term:
        id: MAXO:0000011
        label: physical therapy
    evidence:
      - reference: PMID:24510737
        supports: SUPPORT
        snippet: &#34;Multidisciplinary care includes rehabilitation interventions that have the goal of assisting people to teach their fullest potential despite the presence of a disabling disease.&#34;
        explanation: Review describes how rehabilitation including physical therapy helps maximize independence and function in ALS patients.
  - name: Speech Therapy
    description: &gt;
      Techniques to optimize communication and swallowing safety, including augmentative
      and alternative communication devices.
    treatment_term:
      preferred_term: speech therapy
      term:
        id: MAXO:0000930
        label: speech therapy
    evidence:
      - reference: PMID:24510737
        supports: SUPPORT
        snippet: &#34;This review will present rehabilitation strategies that can be utilized to maximize patient independence, function, safety, and quality of life, and to minimize disease-related symptoms.&#34;
        explanation: Review covers multidisciplinary rehabilitation including speech therapy for ALS patients.
  - name: Percutaneous Endoscopic Gastrostomy
    description: &gt;
      Feeding tube placement to maintain nutrition when swallowing becomes unsafe or
      inadequate due to bulbar involvement.
    treatment_term:
      preferred_term: supportive care
      term:
        id: MAXO:0000950
        label: supportive care
    evidence:
      - reference: PMID:39207520
        supports: SUPPORT
        snippet: &#34;Early discussion of potential treatments such as high-calorie diets or percutaneous endoscopic gastrostomy (PEG) is crucial.&#34;
        explanation: Dysphagia management review underscores PEG as an essential intervention when nutrition is compromised in ALS.
  - name: Multidisciplinary Care
    description: &gt;
      Coordinated care from neurologists, pulmonologists, physical therapists, occupational
      therapists, speech therapists, nutritionists, and palliative care specialists extends
      survival and improves quality of life.
    treatment_term:
      preferred_term: supportive care
      term:
        id: MAXO:0000950
        label: supportive care
    evidence:
      - reference: PMID:24510737
        supports: SUPPORT
        snippet: &#34;Multidisciplinary care includes rehabilitation interventions that have the goal of assisting people to teach their fullest potential despite the presence of a disabling disease.&#34;
        explanation: Rehabilitation review emphasizes multidisciplinary care as core to ALS management to optimize function and quality of life.
datasets:
  - accession: gtex:GTEx_v8_Spinal_cord_cervical_c-1
    title: GTEx v8 Spinal Cord (cervical c-1)
    description: Bulk RNA-seq from healthy cervical spinal cord to provide baseline expression for upper and lower motor neuron pathways affected in ALS.
    organism:
      preferred_term: Homo sapiens
      term:
        id: NCBITaxon:9606
        label: Homo sapiens
    data_type: BULK_RNA_SEQ
    sample_types:
      - preferred_term: spinal cord
        term:
          id: UBERON:0002240
          label: spinal cord
    publication: PMID:33085325
    evidence:
      - reference: PMID:33085325
        supports: SUPPORT
        snippet: &#34;ALS is a neurodegenerative disorder leading to weakness of the bulbar, thoracic, limb, and abdominal muscles with sparing of sensory function.&#34;
        explanation: Clinical overview notes degeneration across spinal motor systems; spinal cord baseline controls contextualize transcriptomic changes in ALS.
  - accession: gtex:GTEx_v8_Skeletal_Muscle
    title: GTEx v8 Skeletal Muscle
    description: Bulk RNA-seq from healthy skeletal muscle to benchmark ALS-related denervation signatures and muscle atrophy pathways.
    organism:
      preferred_term: Homo sapiens
      term:
        id: NCBITaxon:9606
        label: Homo sapiens
    data_type: BULK_RNA_SEQ
    sample_types:
      - preferred_term: skeletal muscle tissue
        term:
          id: UBERON:0001134
          label: skeletal muscle tissue
    publication: PMID:33085325
    evidence:
      - reference: PMID:33085325
        supports: SUPPORT
        snippet: &#34;ALS is a neurodegenerative disorder leading to weakness of the bulbar, thoracic, limb, and abdominal muscles with sparing of sensory function.&#34;
        explanation: Muscle weakness and atrophy are primary clinical consequences in ALS; healthy muscle RNA-seq provides comparative background for ALS muscle involvement.
differential_diagnoses:
  - name: Chronic Inflammatory Demyelinating Polyradiculoneuropathy
    description: Immune-mediated demyelinating neuropathy causing progressive symmetric weakness and sensory loss; may mimic lower motor neuron-predominant ALS.
    disease_term:
      preferred_term: Chronic Inflammatory Demyelinating Polyradiculoneuropathy
      term:
        id: MONDO:0006702
        label: chronic inflammatory demyelinating polyradiculoneuropathy
    evidence:
      - reference: PMID:33085325
        supports: SUPPORT
        snippet: &#34;Some disorders that can mimic motor neuron disease are multifocal motor neuropathy with conduction block, chronic inflammatory demyelinating polyradiculoneuropathy, central nervous system tumors, multiple sclerosis, and polyradiculopathy, among others.&#34;
        explanation: StatPearls review lists CIDP among conditions that can mimic ALS and should be ruled out.
  - name: Multiple Sclerosis
    description: Demyelinating disease of the central nervous system with motor weakness and spasticity that can resemble early ALS presentations.
    disease_term:
      preferred_term: multiple sclerosis
      term:
        id: MONDO:0005301
        label: multiple sclerosis
    evidence:
      - reference: PMID:33085325
        supports: SUPPORT
        snippet: &#34;Some disorders that can mimic motor neuron disease are multifocal motor neuropathy with conduction block, chronic inflammatory demyelinating polyradiculoneuropathy, central nervous system tumors, multiple sclerosis, and polyradiculopathy, among others.&#34;
        explanation: The same review identifies multiple sclerosis as a diagnostic mimic of motor neuron disease.
  - name: Multifocal Motor Neuropathy
    description: Immune-mediated, asymmetric, distal motor neuropathy with conduction block that can present with focal weakness mimicking lower motor neuron ALS.
    disease_term:
      preferred_term: multifocal motor neuropathy
      term:
        id: MONDO:0018979
        label: multifocal motor neuropathy
    evidence:
      - reference: PMID:33085325
        supports: SUPPORT
        snippet: &#34;Some disorders that can mimic motor neuron disease are multifocal motor neuropathy with conduction block, chronic inflammatory demyelinating polyradiculoneuropathy, central nervous system tumors, multiple sclerosis, and polyradiculopathy, among others.&#34;
        explanation: StatPearls review lists multifocal motor neuropathy with conduction block as an ALS mimic that must be ruled out.
</pre>
            </div>
        </div>

        <footer class="page-footer">
            <p>
                Generated from <a href="https://github.com/monarch-initiative/dismech" target="_blank">dismech</a>
                knowledge base
            </p>
            <p style="margin-top: 8px;">
                <a href="https://github.com/monarch-initiative/dismech/blob/main/kb/disorders/Amyotrophic_Lateral_Sclerosis.yaml" target="_blank">View source on GitHub</a>
            </p>
        </footer>
    </div>

    <script>
        function toggleYaml() {
            const content = document.getElementById('yamlContent');
            const toggleText = document.getElementById('yamlToggleText');
            content.classList.toggle('show');
            toggleText.textContent = content.classList.contains('show') ? 'click to hide' : 'click to show';
        }
    </script>
    <script>
        (function() {
            const banner = document.querySelector('.notice-banner');
            if (!banner) return;
            const dismiss = () => banner.remove();
            banner.addEventListener('click', dismiss);
            banner.addEventListener('keydown', (event) => {
                if (event.key === 'Enter' || event.key === ' ') {
                    event.preventDefault();
                    dismiss();
                }
            });
        })();
    </script>
</body>
</html>